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I. Introduction 
 
Dynamic remodelling of the actin cytoskeleton is indispensable for many physiological 
processes, which comprise cell migration, intracellular trafficking of vesicles and organelles, 
cell polarity, and signal transduction. Cell motility defines critical role in various disease 
states like cancer and autoimmunity. Cell motility is a highly coordinated process involving 
dynamic re-organization of the actin cytoskeleton. Actin dynamics comprising polymerization 
and depolymerisation of actin filaments is a tightly regulated process engaging various actin 
binding proteins. The precise molecular mechanism underlying this regulation has been one of 
the domains of intense study for decades in actin biology (Uetrecht and Bear, 2006). At the 
heart of this process of actin regulation is the evolutionarily conserved seven-subunit 
containing Arp2/3 complex, which brings about actin nucleation and branching. Arp2/3 by 
itself is relatively inactive and requires necessary interaction and activation by the WA/VCA 
domain of a nucleation-promoting factor (NPF), such as the SCAR/WASp family of proteins 
(Rodal et al., 2005). The Arp2/3 mediated formation of the F-actin network is a crucial 
process and demands a tight regulation of Arp2/3 complex. One of the protein family that 
seems to contribute to this regulation is the coronin family of proteins (Uetrecht and Bear, 
2006). 
1.1 Coronins 
The coronin family of proteins is prominent amongst the WD-repeat-actin binding proteins 
(Fig.1). They are evolutionarily conserved across different organisms, with origin from simple 
eukaryotes to higher vertebrates. Coronin was first discovered from actin-myosin preparations 
in Dictyostelium discoideum. The term coronin was coined, due to its co localization with the 
actin rich crown-shaped cellular projections (de Hostos et al., 1991). Even though coronin 
protein involvement in actin-dependent processes appears primordial, the individual members 
of the coronin protein family contribute to largely different cellular functions like like signal 
transduction, transcriptional regulation, remodelling of the cytoskeleton, and regulation of 
vesicular trafficking (for an extensive review on coronin proteins see (Clemen et al., 2008)). 
Phylogenetic analyses revealed twelve subfamilies of coronin proteins, comprising seven 
vertebrate paralogs and five subfamilies in nonvertebrate metazoa, fungi and protozoa, some 
of them unclassified so far. Delineation of these twelve subfamily clades has been used to 
propose a comprehensive revision of the coronin protein nomenclature (Fig. 2) (Morgan and 
Fernandez, 2008). Currently, two nomenclature systems are used for coronin proteins. Both 
do not cover all coronin subfamilies and moreover, do not allow unambiguous labelling of 
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gene duplications and isoforms. These disadvantages will be overcome using the revised 
coronin protein nomenclature which is based on evolutionary history, structural change and 
functional adaptation. The coronin subfamilies were united and re-numerated, and ‘CRN’ has 
been proposed as the new symbol for coronin proteins. 
 
                       
 
 
Figure 1. Coronin proteins involved in cytoskeletal F-actin binding and cross-linking, the red circle 
indicates dimerized coronin cross-linking two F-actin filaments. Taken from www.bio.brandeis.edu/faculty. 
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Figure 2. Molecular phylogeny of the coronin family of proteins across different organisms using the 
proposed new nomenclature:  current official symbols in brackets. According to (Morgan and Fernandez, 
2008), taken from (Clemen et al., 2008) 
 
On the basis of amino acid content, mammalian coronins can be distinguished into two 
subfamilies (Rybakin and Clemen, 2005). Short coronins CRN1-6 display three different 
structural domains. The long coronin CRN7 contains the short coronin topology in duplicate. 
Table. 1 illustrates the seven coronins present in mammals (Xavier et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.1 Summary of all mammalian coronin proteins with their corresponding molecular weight, 
amino acid content, percentage identity with Dictyostelium short coronin CRN12, expression and function. 
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1.2 Coronin Structure 
Short coronins exhibit a characteristic three-domain organisation, consisting of an N-terminal 
domain containing a WD repeat-β-propeller structure, an unique C-terminal extension and a 
C-terminal coiled coil domain. (Fig 3). 
1.2.1 N-terminal domain (β-propeller structure) 
The WD40 repeat region is the signature domain of coronin family of proteins (de Hostos, 
1999). The crystal structure of murine CRN4 (synonyms: coronin-1A, coronin-1) lacking its 
coiled coil domain, disclosed a seven-bladed β-propeller structure assembled from five 
canonical WD repeats and two non-canonical repeats (Appleton et al., 2006). The secondary 
structure motif of WD repeat sequence forms four consecutive β-strands connected by loops 
and turns, together defined as β-propeller. Within the propeller, each blade is built up of four 
anti-parallel β-strands extending from the centre to the periphery and the blades are arranged 
in a circular fashion around a central axis. Structurally the innermost β-strands A, B, and C of 
a blade and the outermost strand D are contributed by the second, third and fourth strands of 
one and the first strand of the next WD sequence repeat, respectively. results in stability 
Additionally, two tandem stretches of conserved residues located in the C-terminal extension 
tightly pack against the bottom side of the propeller, which possibly provides further 
structural integrity (McArdle and Hofmann, 2008). Even though β-propeller structures are in 
principle thought to serve as a stable platform for protein-protein interaction, so far only F-
actin has been identified as a potent binding partner of this region in Dictyostelium, yeast and 
mouse CRN1. Therefore, thorough evaluation of this domain may reveal new binding partners 
(Gandhi and Goode, 2008). 
1.2.2 Unique region   
A region in the coronin structure that remains poorly understood is the unique C-terminal 
region. It highly varies in length, sequence and functions (Gandhi and Goode, 2008a). 
Notably this region in S. cerevisiae CRN11 (synonym: Crn1p) and D.melanogaster CRN7 
(synonym: Dpod1) showed sequence homology with the microtubule-binding region of 
mammalian MAP1B. Correspondingly, purified coronin protein of these organisms was 
shown to crosslink microtubules and actin filaments in vitro. In Drosophila, CRN7 is required 
for proper axonal guidance. (Goode et al., 1999; Rothenberg et al., 2003) 
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Figure 3. Coronin domain organisation and protein structure. A. Schematic of coronin domain architecture 
B. Crystral structure of mouse CRN4 β-propeller domain (Appleton et al., 2006) and coiled-coil domain 
(Kammerer et al., 2005). Taken from (Gandhi and Goode, 2008).  
1.2.3 Coiled coil domain 
The very C-terminus of short coronin proteins is composed of a moderately conserved coiled 
coil domain (~35-50 residues, 4-7 heptad repeats) which in CRN4 is identified to posses a 
leucine zipper motif. Eventhough, it is the smallest functional domain of coronin structure, it 
mediates at least three crucial functions like homo-oligomerisation and interaction with F-
actin and Arp2/3 complex (Gandhi and Goode, 2008a). Coiled coil motifs are found to display 
a characteristic hepta-peptide repeat (abcdefg)n, where positions a and b are predominately 
hydrophobic residues and positions e and g are charged residues (McArdle and Hofmann, 
2008). In case of CRN4 threefold repeat of such a characteristic hepta-peptide sequence is 
determined and the motif R-L/I/V-X-X-L/V-E (450-455 in CRN4) has been recognised as a 
mediator of trimerisation in coiled coil (Kammerer et al., 2005). 
1.3 Oligomerisation 
All mammalian short coronins reported so far exhibit a coiled coil domain that has been 
implicated in oligomerisation (Uetrecht and Bear, 2006).A number of studies have shown that 
oligomerization of coronins is exclusively homotypic (Cai et al., 2005; Gatfield et al., 2005; 
Oku et al., 2005). A functional significance of coronin oligomerisation is to execute actin 
filament bundling (Goode et al., 1999). Therefore this observation leads to one possible model 
in which multimerization of the coronin β-propeller would establish actin bundling. Deletion 
of the coiled-coil domain weakened the actin binding affinity of coronin (Cai et al., 2005). 
Another study reports, that the ability of the coiled-coil domain is to increase the actin binding 
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affinity through multimerization of the β-propeller domain (Cai et al., 2007). This gives rise 
to the second possibility, in which individual (non-oligomerised) coronin molecules might 
cross-link actin filaments using two separate actin binding sites, one in the β-propeller and 
another in coiled-coil domain (Gandhi and Goode, 2008). 
1.4 Interactions with Arp2/3 complex 
The diversity of F-actin structures and associated cellular functions depends on many actin-
binding proteins (Cvrckova et al., 2004; Sutherland and Witke, 1999). The submembranous 
area of a cell is enriched in branched F-actin filaments and the Arp2/3 complex (Goley and 
Welch, 2006). Prime examples of a cellular function involving branched F-actin are the 
formation of lamellipodia and cellular motility. The Arp2/3 complex is enriched in the 
periphery of lamellipodia and plays a key role in forming a short-branched F-actin network 
that generates the protruding force depending on a locally well-organized assembly and 
disassembly of F-actin (Fig. 4) (Nabi, 1999; Pantaloni et al., 2001; Ponti et al., 2005; Rybakin 
and Clemen, 2005). The Arp2/3 complex consists of seven subunits. p34 (Arc35, ARPC2) 
together with ARPC4 forms the center of the Arp2/3 complex which initiates site-directed 
branching and elongation of actin filaments and nucleates new actin filaments (Cooper et al., 
2001; Gournier et al., 2001; Pollard and Beltzner, 2002; Stradal and Scita, 2006). 
In addition to F-actin binding the unique C-terminal region and the coiled-coil domain of 
yeast CRN11 was shown to bind with Arp2/3 complex (Humphries et al., 2002; Machesky et 
al., 1997). Further, purified yeast CRN11 was demonstrated to execute inhibitory effect on 
Arp2/3 driven F-actin polymerisation. The inhibitory influence is due to maintenance of 
Arp2/3 complex in an inactive or open confirmation which becomes unavailable for WASp 
activation which results in Arp2/3 mediated actin polymerisation. CRN11 constructs lacking 
the coiled-coil domain were inefficient to interact with Arp2/3 complex (Rodal et al., 2005). 
Colocalization studies of CRN1 (synonyms: coronin-1B, coronin-2) with Arp2/3 complex 
was also reported in a variety of cells. In addition, mouse CRN4 was shown to control steady-
state F-actin levels via an Arp2/3 complex driven mechanism in T-lymphocyctes (Foger et al., 
2006). 
1.5 Coronin regulation by phosphorylation 
A number of evidence demonstrates mammalian coronins to be regulated by phosphorylation 
(Uetrecht and Bear, 2006). CRN4 was shown to be phosphorylated in vitro by purified PKC, 
which is stimulated in vivo by PMA treatment (Itoh et al., 2002). In addition, PKC inhibitor 
celerythrine was shown to block both phosphorylation and dissociation of CRN4 from 
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phagosomes (Gatfield et al., 2005). Similar studies pertaining to PKC stimulation with 
phorbol ester PMA and down regulation using PKC inhibitors were shown to be responsible 
for phosphorylation of CRN1 (Cai et al., 2005). Further, CRN7 was shown to get 
phosphorylated on tyrosine residues (Rybakin et al., 2004). 
 
                   
 
Figure 4. Arp2/3 mediated actin polmerisation at the leading edge. N-WASP is activated and targeted to the 
membrane by signaling molecules (circled 1). G-actin and the Arp2/3 complex together bind to N-WASP 
(VCA), forming a branching complex (circled 2), binding of the branching complex with a filament leads to the 
formation of a branch (circled 3). Both the branches grow at equal rates. N-WASP catalyzes several consecutive 
cycles of branching. Taken from (Pantaloni et al., 2001). 
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1.6 Coronins in disease 
Since regulation of actin dynamics is an essential part of many disease states, actin binding 
coronin proteins could play a role in diseases. A role of CRN4 in pathogenic bacterial 
infection can be considered as one of the best-characterized examples (Ferrari et al., 1999). A 
well established mechanism to destroy engulfed bacteria by macrophages are through 
controlled membrane fusion of phagosomes with lysosomes, wherein delivery of lytic 
enzymes acidify phagolysosomes resulting in effective destruction of bacteria (Anes et al., 
2003; Vergne et al., 2004). Actin polymerisation around nascent phagosomes plays a potential 
role in driving these critical vesicle fusion events, emphasizing importance of actin dependent 
process in immune response to combat bacterial infections (Anes et al., 2003). Recent studies 
reveal that pathogenic Mycobacterium tuberculosis are able to circumvent the normal immune 
response by macrophages through retaining CRN4 function to alter the actin dynamics on the 
phagosome, thereby preventing the maturation of phagosomes and permitting bacterial 
propagation within the macrophage (Ferrari et al., 1999). Further CRN1 was linked with 
neurite formation and axon regeneration with subsequent spinal cord injury (Di Giovanni et 
al., 2005). 
1.7 CRN2 (coronin-1C, coronin-3) 
CRN2 (current official symbol: CORO1C, current official name: coronin-1C, most common 
synonym: coronin-3) is a short coronin protein (Rybakin and Clemen, 2005) of 474 amino 
acids with a calculated molecular mass of 53 kDa in human and murine cells; the apparent 
molecular mass from SDS-PAGE analysis is approximately 57 kDa (Fig.5). Based on the 
crystal structure of CRN4 a structural homology model of CRN2 was proposed (Fig.6) 
(McArdle and Hofmann, 2008). At the subcellular level CRN2 exists in two different pools, 
an actin cytoskeleton associated non-phosphorylated pool and a diffusely distributed 
phosphorylated cytosolic pool and represented as multiple spots on 2D gels (Spoerl et al., 
2002). CRN2 has been identified as an actin filament-crosslinking and bundling protein 
(Hasse et al., 2005; Spoerl et al., 2002) involved in distinct cellular functions like 
proliferation, migration, formation of cellular protrusions, endocytosis and secretion 
(Rosentreter et al., 2007). Recent studies indicate CRN2 as an important factor in the 
development of the murine brain (Hasse et al., 2005) as well as a potential marker for 
melanoma progression (Roadcap et al., 2008). 
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Figure 5. Human CRN2 domain organisation. Mapped membrane and actin binding sites are indicated. Taken 
from (McArdle and Hofmann, 2008). 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6. Putative topology of CRN2 based on structural information of CRN4 showing the N-terminal 7-
blades of the β propeller structure and the C-terminal extension and coiled coil domain. Taken from (McArdle 
and Hofmann, 2008). 
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1.8 Aim of the work 
Coronins are one the most versatile family of proteins evolutionarily well conserved amongst 
eukaryotes and mammals including Dictyostelium, Drosophila, mouse and humans. With its 
origin as a single gene in simple eukaryotes, the mammalian coronin gene family has shown 
expansion to include seven members. Human CRN2 is one of the ubiquitously expressed 
short coronin proteins with F-actin binding and cross-linking properties. In this thesis work 
we attempt to characterize human CRN2 with respect to its biochemical and cellular 
functions.  
 
• We investigate the role of CRN2 in cellular processes in association with actin 
cytoskeleton through over expression of coronin domains, down-regulation of CRN2 
levels using the RNAi technique and co-immunoprecipitation studies. 
• We analyse the expression of CRN2 in normal as well as various types of malignant 
and benign human brain tumours. Further we pursue in vitro functional studies using 
CRN2 knockdown in glioblastoma cells and investigate the role of CRN2 in regulating 
cell proliferation, migration and invasion. 
• We study functional and structural diversity of three human CRN2 isoforms, 
designated as CRN2i1, CRN2i2 and CRN2i3. 
• We investigate the regulation of the cellular activity of CRN2. 
 
Note: In some of the figures CRN2 is specified as coronin-3 or coronin-1C which are 
synonyms of CRN2. 
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1.9 Preliminary publications 
Significant parts of this work have been published as research articles: 
 
• Xavier C-P, Rosentreter A, Reimann J, Cornfine S, Linder S, Hofmann A, Morgan 
RO, Fernandez MP, Stumpf M, Müller R, Jungbauer T, Schröder R, Noegel AA, 
Clemen CS. Coronin-1C isoforms are novel components of podosomes and 
sarcomeres. Submitted for publication. 
• Xavier C-P, Eichinger L, Fernandez MP, Morgan RO, Clemen CS. Evolutionary and 
Functional Diversity of Coronin Proteins. In: The Coronin Family of Proteins. Vol. 48. 
Eds.: Clemen CS, Eichinger L, Rybakin V. Landes Bioscience & Springer. 2008. 
ISBN 978-0-387-09594-3. Open access at http://www.eurekah.com/chapter/3808.  
• Thal DR, Xavier C-P, Rosentreter A, Waha A, Pietsch T, Stumpf M, Noegel AA, 
Clemen CS. Expression of coronin-3 (coronin-1C) in diffuse gliomas is related to 
malignancy. J Pathol 2008 214:415-24. Equal contributors.  
• Rosentreter A, Hofmann A, Xavier C-P, Stumpf M, Noegel AA, Clemen CS. Coronin 
3 involvement in F-actin dependent processes at the cell cortex. Exp Cell Res 2007 
313:878-95. 
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II. Results 
2.0 Role of CRN2 in cellular processes 
2.1 CRN2 interacts with the F-actin cytoskeleton in vivo 
In HaCaT cells endogenous CRN2 shows a characteristic however not continuous localization 
to the submembranous area. This localization is particularly obvious in cells, which exhibit a 
strong accumulation of actin filaments underneath the plasmamembrane. CRN2 additionally 
was detected at punctate structures in the cytoplasm, with a perinuclear accumulation of these 
spots (Fig. 7A, upper panel). To confirm the subcortical enrichment of CRN2, HaCaT cells 
were retrovirally transduced to express GFP–CRN2. The distribution of GFP–CRN2 (Fig. 7B, 
left panel) and endogenous CRN2 (Fig. 7B, right panel; this is a higher magnification of the 
upper left image of Fig. 7A) are congruent, however, the GFP–signal of CRN2 more clearly 
shows the protein's cortical localization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CRN2 shows an F-actin-dependent distribution in HaCaT cells. A. HaCaT cells treated with or 
without latrunculin B were first fixed with 4% paraformaldehyde and then permeabilized with 0.2% Triton X-
100 (data shown). CRN2 was detected using mAb K6-444 and goat anti-mouse Cy3 as secondary antibody; F-
actin was visualized using FITC–phalloidin. 
 
This cortical localization of endogenous CRN2 is maintained after Triton X-100 
permeabilization prior to fixation (data not shown), indicating a stable association of coronin3 
and F-actin in vivo. By contrast, HaCaT cells treated with latrunculin B prior to fixation never 
showed any accumulation of CRN2 underneath the plasmamembrane, but CRN2 appears in 
spots clearly distinguishable from the remaining F-actin staining (Fig. 7A, lower panel). The 
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latter Factin structures represent a pool that is resistant to the treatment with latrunculin B 
(Ammar et al., 2001). HaCaT cells treated with latrunculin B and Triton X-100 prior to 
fixation neither showed a structured staining of CRN2 nor of F-actin (data not shown); most 
of both proteins disappeared and only a diffuse residual staining remained. 
                
 
Figure 7, continued. B Higher magnifications of HaCaT cells expressing GFP–CRN2 (left; same expression 
vector is used in HEK293 cells, Fig. 7B) and of antibody-stained endogenous CRN2 (right; higher magnification 
of the upper left image from A) demonstrate a submembranous localization of CRN2. C. Corresponding to A, 
cells were incubated with or without latrunculin B, washed with Triton X-100, and lysed cells were separated by 
differential centrifugation. Samples of the Triton X-100 soluble fraction (Triton wash) and the centrifugation 
steps were analyzed by SDS–PAGE followed  by Western blotting using antibodies against CRN2 (mAb K6-
444) and β-actin  S, supernatant, P. pellet fractions. 
 
These observations were confirmed by differential centrifugation and immunoblotting (Fig. 
7C). The relative distribution of CRN2 within different fractions of each experiment can be 
compared. In untreated HaCaT cells CRN2 is most abundant in the 100,000 g pellet; minor 
amounts are detectable in the 10,000 g pellet and in the 100,000 g supernatant. CRN2 as well 
is detected in the Triton X-100 soluble fraction (Triton X-100 wash). Note that the 10,000 g 
pellet contains the crude cytoskeletal fraction (highly crosslinked actin filaments) and the 
pellet of 100,000 g includes cytoskeletal elements associated with membranes (free or loosely 
crosslinked actin filaments) (Fox, 1985; Lehtonen et al., 2002; Tohyama et al., 1994). After 
treatment with latrunculin B the amount of CRN2 in the 100,000 g pellet is markedly reduced 
and instead appears in the 100,000 g supernatant. The data from immunofluorescence analysis 
and differential centrifugation confirmed a binding of CRN2 to F-actin as previously 
described (Spoerl et al., 2002) and clearly demonstrate a localization of CRN2 that depended 
strongly on F-actin in vitro as well as in vivo. 
2.2 Absence of CRN2 or lack of single domains inhibits fibroblast migration 
To determine the contribution of CRN2 in cellular processes, we investigated wound healing 
of confluent layers of HEK293 cells stably expressing CRN2 proteins. Wound healing was 
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monitored over 10 h (Figs.8A, B). We observed a statistically significantly reduced velocity 
of wound closure in case of all CRN2 polypeptides compared to WT cells, which exhibited 
the fastest wound closure with an average velocity of 23 µm/h. Comparing CRN2-NWDC (20 
µm/h) with the other CRN2 polypeptides demonstrated that except for CRN2-∆CC (21 µm/h; 
F-actin binding regions are present in this fusion protein) all proteins led to statistically 
significantly slower wound closure velocities. Cells, which express CRN2-NC and CRN2-
NGC, lacking the central WD40 repeats or carrying a glycine loop instead, showed reduced 
velocities of 14 µm/h and 15 µm/h respectively. The strongest impairment in wound healing 
was noted for CRN2-∆NC (11 µm/h) and CRN2-WD (11 µm/h). 
 
 
Figure 8. CRN2 knockdown using siRNA as well as expression of EGFP–CRN2 fusion proteins affect 
wound healing. A. Column on the left presents the wounds immediately after wounding a confluent HEK293 
cell layer with a needle, the column on the right presents the wounds after 10 h. Cells expressing CRN2-WT 
(endogenous CRN2), CRN2-NWDC, and CRN2-NC are shown. Scale bar: 100 µm. B. Effect of coronin fusion 
proteins on wound healing. Error bars indicate the standard deviation from three independent experiments, each 
with three determinations of the width of the wound. p-values refer to the population expressing CRN2-NWDC 
and were calculated by Student's t-test; p <0.05 is significant. CRN2-∆CC displayed least effect in wound 
closure velocity with p=0.700 in comparison to CRN2-NC (p=0.006), CRN2-NGC (p=0-004). Both CRN2-∆NC 
and CRN2-WD (p <0.001) exhibited highest inhibitory effect in wound closure. 
 
To further support the involvement of CRN2 in wound healing we performed wound healing 
assays with NIH3T3 fibroblasts in which the level of CRN2 was significantly decreased by 
RNAi silencing. 48 h after two treatments with a mixture of four different siRNA duplexes, 
confluent monolayers of wild-type NIH3T3 and siRNA transfected NIH3T3 cells were 
wounded. RNAi-treated cells showed a significantly delayed wound closure with an averaged 
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velocity of 25 µm/h compared to untransfected wild-type cells (33 µm/h). Control cells treated 
only with luciferase-specific siRNA or with transfection reagent showed no impairment. 
Immunofluorescence images of CRN2 siRNA-treated cells did not reveal any obvious change 
and behaved like wild-type in the F-actin staining, although the CRN2-specific signal 
intensity was reduced in virtually all cells. The reduction in CRN2 expression calculated from 
Western blotting was approximately 90% (Fig. 8C). 
 
 
Figure 8, continued. C. Representation of the wound healing behaviour of wt and siRNA-treated NIH3T3 cells. 
Error bars indicate the standard deviation from three independent experiments, each with five determinations of 
the width of the wound. Western blot shows a ~90% reduction of the CRN2 expression, immunofluorescence 
imaging as well indicate a decreased expression level of CRN2, but no obvious change in the F-actin 
cytoskeleton. The p-value was calculated with single factor ANOVA; p <0.05 is significant. 
2.3 Expression of the WD-repeat domain of CRN2 inhibits cell proliferation 
We addressed the effects of CRN2 on cell proliferation and cytokinesis. Wild-type HEK293 
and the stably transfected cell populations, which exhibited differences compared to CRN2-
NWDC in the wound healing assay, were seeded in low concentrations and counted again 
after 3 days to calculate cell proliferation. CRN2-NWDC, CRN2-NC, CRN2-NGC, and wild-
type cells showed only slight and insignificant differences in cell proliferation. A statistically 
significant inhibition of proliferation was detected for cells expressing CRN2-∆NC and 
CRN2-WD (Fig.9A). 
To verify that the reduced cell proliferation rate is not due to defects in cytokinesis, we 
repeated the experiment and determined the number of multinucleated cells after 3 days of 
cultivation (Fig. 9B). Here, only CRN2-NWDC and wild-type HEK293 cells showed similar 
low levels of multinucleated cells, but cells transfected with any of the CRN2 domain 
constructs showed approximately five-fold increased levels of multinuclear cells. An 
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evaluation of the number of cells harboring two, three, or four and more nuclei detected no 
further differences. Note that CRN2-NC and CRN2-NGC induce defects in cytokinesis 
though no change in proliferation rate is detected. Only CRN2-∆NC and CRN2-WD exhibit 
both, a reduced cell proliferation rate and an increased number in multinucleated cells. Cell 
proliferation and cytokinesis independently are changed by the presence of CRN2 peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. EGFP–CRN2 fusion proteins affect cell proliferation and cytokinesis. A. Proliferation rates of 
HEK293 cells expressing the indicated fusion proteins after 3 days of cultivation. The error bars represent the 
standard deviation of three independent experiments. p-values refer to the CRN2-NWDC cell population and 
were calculated by Student's t-test; p <0.05 is significant. B. Bars indicate the number of cells having more than 
one nucleus per cell for different HEK293 cell populations. The values are from two independent experiments 
with approximately 185 cells analyzed per cell line. A significantly high percentage of multinucleated cells were 
seen in CRN2-WD, ∆NC, NC, and CRN2-NGC in comparison to CRN2-WT (endogenous coronin) and CRN2-
NWDC, where lowest percentage was measured. 
2.4 CRN2 participates in the formation of cellular protrusions 
One major aspect of cell migration is the formation of cellular protrusions. Therefore, the 
activity of single wild-type HEK293 cells or cells expressing CRN2 domains were recorded 
over 30 min (Fig.10A). Figure 10 is representative of several experiments. Wild-type 
HEK293 cells could not be distinguished from the CRN2-∆CC, CRN2-NC, and CRN2-NGC 
populations with respect to the number of protrusions formed. CRN2-NWDC cells exhibit a 
slightly increased number of protrusions, which was also detected by immunofluorescence 
images of fixed cells. A markedly reduced number of lamellipodia as well as filopodia were 
detected in HEK293 cell populations expressing CRN2-∆NC and CRN2-WD. Further they 
showed the lowest frequencies of changes in the number of forming or retracting protrusions 
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(2.5 and 1.0, respectively). Although HEK293 populations expressing CRN2-NC do not 
exhibit a change in the number of protrusions, the frequency of their formation is reduced 
(Fig.10B). The presence of the glycine loop between the N- and C-terminus (CRN2-NGC) 
ameliorates the defect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. CRN2 fusion proteins alter the activity of HEK293 cells. The changes in the number of cellular 
protrusions including lamellipodia and filopodia followed over 30 min for the wt and cell populations expressing 
the CRN2 polypeptides indicated are given. A. Graph is representative for several independent experiments. 
 B. Mean frequency of changes in the number of protrusions of each cell population over the time. A 
significantly reduced number of lamellipoidia or filopodia was demonstrated by CRN2∆NC and CRN2-WD. 
Unlike CRN2-WD, all other constructs (CRN2-WT, NWDC, ∆CC, NC, NGC) displayed almost similar number 
of cellular protrusions without notable difference. 
2.5 Full-length CRN2 is essential for the process of fluid phase pinocytosis 
To investigate further possible roles of CRN2 at the submembranous cytoskeleton, the uptake 
of material was investigated. Phagocytosis is restricted to specialized mammalian cells and 
was not studied. Fluorescent transferring uptake was used to quantify the receptor-mediated 
and clathrin-associated endocytosis. This process was found to be unchanged in all HEK293 
cell populations compared to the wild-type (data not shown). In contrast, pinocytosis of the 
fluid phase marker HRP was significantly affected (Fig.11). CRN2-∆NC and CRN2-WD 
caused a distinctly reduced pinocytotic activity, while CRN2-NC and CRN2-NGC exhibited 
an intermediate decrease of pinocytosis. 
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Figure  11. CRN2 proteins influence fluid phase pinocytosis. HEK293 cells expressing CRN2 fusion proteins 
were harvested and lysed after exposing them for 60 min to HRP-containing medium (2 mg/ml). The 
experiments were carried out three times in duplicate. The results were normalized to the total protein amount. p-
values calculated by single-factor ANOVA refer to the population of CRN2-NWDC; p <0.05 is significant. A 
statistically considerable reduction in pinocytotic activity was measured in case of CRN2-∆NC (p=0.021) and 
CRN2-WD (p=0.033). Intermediate pinocytotic activity was displayed by CRN2-NGC (p=0.043) and CRN2-
NC,p=0.063) with no difference in case of CRN2-NWDC and CRN2-WT (p=0.948). 
2.6 CRN2 forms a complex with the Arp2/3-complex and with cofilin 
Previous studies had reported an interaction between yeast CRN11 and mammalian CRN1 
and the Arp2/3 complex (Humphries et al., 2002) (Cai et al., 2005; Rodal et al., 2005). Here 
we tested complex formation with CRN2. HEK293 cells expressing CRN2-NWDC were used 
for several independent co-immunoprecipitation assays employing a monoclonal GFP-
antibody (Fig.12). Prior to harvest, the cells were treated with latrunculin B to prevent 
unspecific co-precipitation of proteins bound to and tied together by F-actin. Precipitated 
proteins were analyzed by mAb K6-444 detecting the endogenous CRN2 as well as the 
EGFP–fusion protein. As expected, the endogenous CRN2 binds to and co-precipitates with 
EGFP–CRN2, most likely in a heterotrimeric complex (Spoerl et al., 2002). Using antibodies 
specifically recognizing cofilin and the p34 (arc35) subunit of the Arp2/3 complex, we 
detected these proteins in the immunoprecipitate. For control we used BiP/GRP78- and β-
actin-specific antibodies excluding unspecific binding of the cell lysate or actin to the protein 
G sepharose beads. 
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Figure 12. Endogenous CRN2, p34-Arc, and cofilin co-immunoprecipitate with EGFP–CRN2. HEK293 
cells expressing EGFP–CRN2 were treated with latrunculin B and used for co-immunoprecipitations with an 
anti-GFPmAb. Samples were analyzed by immunoblotting using antibodies specifically recognizing CRN2, p34-
Arc, and cofilin (co-IP). For control the experiment was carried out with cell lysate (beads only) or with anti-
GFP mAb only, and the blot was probed with antibodies directed against BiP/GRP78 and β-actin. Arrowhead, 
endogenous CRN2; double-arrowhead, EGFP–CRN2; arrow, p34 (arc35); asterisk, unspecific bands of the GFP–
antibody solution. The signals for BiP/GRP78, CRN2, and p34-Arc are from the same membrane probed 
serially; signals for β-actin and cofilin are from parallel Western blots. 
2.7 Structural properties of CRN2 deduced from the CRN4 crystal structure 
Originally, CRN2, like all short coronin proteins, was thought to consist of an N-terminal 
domain (aa 1–71), a core region containing five WD40-repeats (aa 72–299), and a C-terminal 
domain (aa 300–474) (de Hostos, 1999; Rybakin and Clemen, 2005). Based on a manual 
amino acid alignment, we have proposed a CRN2 structure similar to the seven-bladed 
propellers known from other WD40 proteins [Hofmann and Clemen, unpublished]. The two 
additional WD40-repeats of CRN2 are located in the N-terminal domain (aa 1–71) and the 
conserved part of the C-terminus (aa 300–404) (Fig.13); aa 1–11, the coronin-specific 
signature motif, and 348–404 do not contribute to the respective WD40-repeats. This 
hypothesis was confirmed by the crystal structure of truncated CRN4 (aa 10–aa 400) which 
revealed the presence of seven WD40-repeat domains (Appleton et al., 2006) which had also 
been predicted by (Gatfield et al., 2005).Based on these data of CRN4, we investigated the 
overall structure as well as intramolecular interactions of CRN2. It seems highly likely that 
CRN2 adopts a similar N-terminal fold as CRN4 sharing the characteristic feature of the first 
N-terminal beta strand completing the last propeller blade of the WD40-repeat domain 
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constituted by amino acids 13–348 (Fig.13). As identified in CRN4 intramolecular 
interactions might stabilize the C-terminal extension by anchoring it to the WD40 beta-
propeller. The main contributors to these interactions are hydrogen bonds of Tyr362 to the 
backbone carbonyl groups of Val327 and Glu331, and the side chain interactions of the N-
terminal Lys9 with Arg352 and Asp360. There is also a hydrophobic interface being formed 
between residues His139, Ile157, Trp182 and Ile189 from the WD40-repeat domain and 
Trp377 and Phe378 from the C-terminal extension. Since there is a high degree of 
conservation between CRN4 and CRN2 in these regions, the significance of these interactions 
concluded from the CRN2 homology model seems quite likely. Analyses of structure and 
electrostatic potential of the surface of CRN4 resulted in the identification of potential F-actin 
binding sites. They comprise a region on the top of propellers 1, 6, 7, and a second region on 
the bottom side of propellers 6 and 7 (Appleton et al., 2006). Similar regions can be assigned 
to CRN2. The F-actin binding site in CRN4 also includes a stretch of positively charged 
amino acids (400–416 (Gatfield et al., 2005)  in the C-terminal extension, which is mirrored 
in CRN2 (aa 398–aa 419; KNRDLKVVKKNILDSKPTANKK).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Homology model of CRN2 (aa 7–400). The model has been generated with the CRN4 crystal 
structure (Appleton et al., 2006) [PDB accession number 2aq5] as template using MODELLER (Sali and 
Blundell, 1993) and a manual alignment of amino acid sequences. The seven-blade propellers of the N-terminal 
WD40-repeat domain are colored individually and annotated by their sequential order. The C-terminal extension 
is shown in brown and polar interactions stabilizing its fold are drawn explicitly. The yellow dot surface maps a 
hydrophobic interface formed by residues His139, Ile157, Trp182, Ile189, Pro203, Trp377, and Phe378. Figure 
prepared with PyMOL (W.L. DeLano, 2002). Taken from (Rosentreter et al., 2007). 
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3.0 Expression of CRN2 in diffuse gliomas is related to malignancy 
3.1 CRN2 is expressed in a subset of human brain tumours and in reactive astrocytes 
The expression of CRN2 in normal human brain and in brain tumours was determined by 
histopathological analysis and immunoblotting. Normal human brain tissue in general 
exhibited virtually no CRN2 protein (data not shown). The white matter did not show CRN2 
immunoreactive cells. Cortical neurons, on the other hand, were faintly labelled. Other groups 
of neuronal cells in the hippocampus (CA1-4, dentate gyrus), the neocortex and the 
cerebellum (Purkinje cells), as well as subpial astrocytes in neocortical layer I were also 
faintly labelled (Table 2).  
 
Table 2. Expression of CRN2 in the human brain and in different types of human brain tumours. +, 
expression of CRN2; (+), weak expression of CRN2; −, no expression of CRN2; n, number of cases; IHC, 
immunohistochemistry; WB, western blotting;  , autopsy cases from which different brain regions, i.e. cerebral 
cortex, hippocampal formation and cerebellum, were observed. 
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Figure 14. Expression of CRN2 in diffuse gliomas. A. Low-grade diffuse gliomas exhibited less prominent 
expression of CRN2 than high-grade gliomas. The diffuse astrocytoma showed CRN2 expression in no more 
than 50% of the tumour cells. Oligodendrogliomas often failed to express CRN2 (shown here) or were only 
weakly stained (refer to Table 2). In benign oligoastrocytomas CRN2 was mainly expressed in the astroglial 
component (arrowheads), while the oligodendroglial component was either not or only weakly stained (arrows). 
B. In contrast, expression of CRN2 in an increased number of tumour cells was noted in high-grade diffuse 
gliomas. Anaplastic astrocytomas and anaplastic oligodendrogliomas exhibited CRN2 immunoreactivity in 
>50% of the tumour cells. In anaplastic oligoastrocytomas, CRN2 was expressed in the malignant tumour 
component. In the presented case, CRN2 expression was mainly found in the astroglial component (arrowheads), 
whereas the oligodendroglial component appeared well differentiated and did not stain for CRN2(arrows). In 
anaplastic oligoastrocytomas with a malignant transformation of the oligodendroglial component, this 
component also started to express CRN2.  In glioblastomas, nearly all tumour cells showed CRN2 expression.   
 
The expression of CRN2 in tumours varied among different types of brain tumour. No 
expression of CRN2 was detectable in tumours of neuronal origin, viz in the desmoplastic 
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medulloblastomas and a neuroblastoma (Table 2). On the other hand, two benign tumour 
entities, benign meningiomas and pilocytic astrocytomas, exhibited a high number of tumour 
cells expressing CRN2 (Table 2). Low-grade diffuse astrocytomas, oligodendrogliomas and 
oligoastrocytomas, however, showed a limited number of CRN2-positive tumour cells 
(Fig.14A and Table 2; note that oligodendrogliomas showed either no or a small number of 
tumour cells expressing CRN2), while highgrade anaplastic astrocytomas, anaplastic 
oligodendrogliomas, anaplastic oligoastrocytomas and glioblastomas exhibited high numbers 
of CRN2-positive tumour cells (Fig. 14B and Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Expression of CRN2 in the astroglial and oligodendroglial component of anaplastic 
oligoastrocytomas. A: Most of the astroglial tumour cells expressed CRN2 (arrowheads). The oligodendroglial 
component with anaplastic features such as mitoses (asterisk) showed mild to moderate levels of CRN2 (arrows). 
B: Double label immunofluorescence of another anaplastic oligoastrocytoma showed no expression of CRN2 in 
the oligodendroglial component. This component is characterized by a perinuclear staining pattern of the tumour 
cells with anti-MAP2. C: The astroglial tumour component of this tumour exhibited a co-localization of CRN2 
with MAP2. This expression of MAP2 in a pattern showing cell processes indicated the astroglial tumour cell 
nature of these cells. 
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Figure 16. Expression of CRN2 in different regions of a glioblastoma multiforme. A: In a glioblastoma 
multiforme nearly all tumour cells expressed CRN2. B: The most prominent expression, however, was detected 
in areas of vital tumour with microvascular proliferation. C: Surviving tumour cells near areas of palisading 
necroses were only weakly labeled with anti-CRN2. The boxes in A indicate the areas enlarged in B and C. 
 
Within mixed gliomas, i.e. oligoastrocytomas and anaplastic oligoastrocytomas, different 
expression patterns of CRN2 within both tumour components were detected: the astroglial 
tumour cells more often expressed CRN2 than those of the oligodendroglial component 
(Fig.15). Double-label immunofluorescence of CRN2 and MAP2 confirmed the tumour cell 
nature of the CRN2-positive astroglial cells in oligoastrocytomas. However, in some cases the 
oligodendroglial compartment also showed a prominent CRN2 expression, mostly occurring 
in anaplastic oligoastrocytomas with features of malignancy of the oligodendroglial 
component, such as mitotic figures. 
Moreover, particularly in glioblastomas that expressed CRN2 in nearly all tumour cells, a 
variation in the expression of CRN2 within the tumour was seen (Fig.16). Tumour cells 
adjacent to proliferating microvessels in the tumour periphery (Fig. 16B) exhibited a stronger 
CRN2 staining than those adjacent to areas of necrosis (Fig.16C). 
The matrix of brain tumours contains a varying number of reactive astrocytes, non-malignant 
but activated and migrating cells that also expressed CRN2 (Fig.17F-H). These CRN2-
positive reactive astrocytes, however, are not restricted to tumours. In the vicinity of other 
brain lesions, ie infarcts and traumatic lesions, expression of CRN2 was also detectable within 
reactive astrocytes (Fig.17A). In contrast, non-specific astroglial activation in the absence of a 
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circumscribed lesion, e.g. in the course of epilepsy, showed only a faint expression of CRN2 
in astrocytes (Fig. 17C-E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Expression of CRN2 in reactive astrocytes and microglial cells. A: Activated astrocytes highly 
exhibiting CRN2 were present in the brain close to an infarct lesion at the stage at which gliosis was beginning. 
B: In an infarct lesion in the stage of resorption macrophages showing foam cell morphology were labelled by 
anti-CRN2. C-E: Gliosis in a case of chronic epilepsy showed weak CRN2 expression in reactive astrocytes (C, 
arrows), which also exhibited glial fibrillary acidic protein (GFAP) (D, arrows), and in perivascular macrophages 
(C, arrowheads) identified by their CD-68 expression (E, arrowheads). F-H: CRN2 was detected in tumour-
associated reactive astrocytes. Reactive astrocytes were identified comparing the staining of CRN2, GFAP, and 
MAP2. The latter specifically marked tumour cells (Rosentreter et al., 2007) (arrowheads), whereas GFAP 
stained both tumour cells (arrowheads) and reactive astrocytes (arrows). Based on the different morphology of 
tumour cells and reactive astrocytes, CRN2-positive cells in this low-grade astrocytoma were predominantly 
classified as reactive astrocytes (arrows), while most tumour cells failed to stain for CRN2 (arrowheads). 
3.2 CRN2 expression correlates with the grade of malignancy in diffuse gliomas 
As our data showed that diffuse gliomas, i.e. astrocytomas, oligodendrogliomas and 
oligoastrocytomas, exhibited increasing numbers of tumour cells expressing CRN2 with 
increasing WHO grade, which indicates the malignant potential of a tumour, we focused on 
these tumours (Fig.18A). A semiquantitative analysis of vital tumour expressing CRN2 
demonstrated that oligodendrogliomas, diffuse astrocytomas and oligoastrocytomas contained 
  Results                                                                                                                                26                       
 
only a small number of tumour cells positive for CRN2 (Fig.18A). In contrast, usually more 
than 50% of the tumour cells were stained by mAb K6-444 anti-CRN2 antibodies in 
malignant gliomas (Fig.18A; p < 0.01). Accordingly, western blots of gliomas showed 
increased levels of CRN2 compared to normal tissue of grey and white matter (Fig.18B,C; p 
< 0.05). Although Western blotting in general confirmed the increased expression of CRN2 in 
diffuse gliomas with their grade of malignancy, the analysis of tissue homogenates showed 
varying expression levels. This was particularly visible in low- and high-grade astrocytomas 
(Fig.18B, C). The reason behind this is that the area of tumour tissue used for immunoblotting 
is not exactly defined. Therefore, two factors will interfere with the determination of the 
CRN2 expression by immunoblotting, but not by immunostaining. First, the expression levels 
of CRN2 vary in tumour cells within different regions of a certain tumour (Fig.19); and 
second, the tumour matrix contains a varying number of reactive astrocytes that also express 
CRN2 (Figs.18A; 17F-H). 
 
 
Figure 18 Quantification of the expression of CRN2 in tumour cells and tumour tissues. A. Tumour cell 
expression in relation to malignancy was determined by quantification of the immunohistochemical expression 
of CRN2 in diffuse gliomas. With increasing malignancy, as indicated by the WHO grade, the number of tumour 
cells expressing CRN2 increased. Mean and standard deviation are presented; *** indicates p < 0.01, as 
calculated by the Kruskal–Wallis H-test and the trend-test. Tumourcell expression in different types of gliomas 
was analysed by quantification of the immunohistochemical staining pattern of CRN2 within the different types 
of gliomas. The highest numbers of tumour cells expressing CRN2 were present in anaplastic astrocytomas, 
anaplastic oligoastrocytomas and in glioblastomas. * Indicates p < 0.05, as determined by the Mann–Whitney U-
test to compare the different types of tumours. p values were corrected for multiple testing. Expression in 
tumour-associated reactive glial cells in diffuse gliomas was observed by the semiquantitative assessment of the 
number of reactive astrocytes expressing CRN2associated with diffuse gliomas. Oligodendrogliomas, anaplastic 
oligodendrogliomas, astrocytomas and anaplastic astrocytomas were frequently associated with reactive glial 
cells that also exhibited CRN2. Oligoastrocytomas, anaplastic oligoastrocytomas and glioblastomas appeared to 
be less frequently associated with a reactive gliosis. However, there was a wide range of the degree of gliosis in 
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each tumour entity. Therefore, the trend seen in the diagram did not reach significance (Poisson regression 
analysis, p = 0.8254; deviance, 301 812). 
 
 
Figure 18, continued. B. Western blot analysis of the different types of diffuse gliomas exhibited weak to 
moderate CRN2 expression levels in tissue samples of astrocytomas (AII), oligodendrogliomas (OII), 
oligoastrocytomas (OAII) and anaplastic astrocytomas (AAIII). Two anaplastic astrocytomas (AAIII), the 
anaplastic oligodendroglioma (AOIII) and the glioblastomas (GBMIV) showed a strong expression of CRN2. 
Pilocytic astrocytomas (pA), loaded as positive controls, exhibited moderate CRN2 expression levels. Normal 
human brain tissue of grey (GM) and white matter (WM) did not express more than traces of CRN2; β-actin is 
given as a loading control. 
 
 
 
 
 
 
 
 
 
 
Figure 18, continued. C. CRN2 expression in tumour tissue observed by quantitative western blotting. Tumour 
tissue expression in relation to malignancy showed an increase from benign diffuse gliomas to high-grade 
glioblastomas (*, Kruskal–Wallis H-test, Trend-test, p < 0.05). Tumour tissue expression in different types of 
gliomas exhibited a nearly similar pattern as the immunohistochemical analysis but failed significance because 
of the possible interference of reactive glial cells in this small sample. 
3.3 CRN2 knockdown inhibits cellular functions related to tumour malignancy 
U373 and A172 glioblastoma cells, commonly used to study glioma-related cellular functions, 
express high levels of CRN2. To address the question of whether the expression of CRN2 in 
gliomas has an impact on tumour cell proliferation, migration, and invasion, we employed 
lentivirus mediated shRNA-dependent knockdown of CRN2 in U373 and A172 glioblastoma 
cells, which resulted in a ~95% CRN2 protein reduction (Fig. 19A). 
 
 
 
  Results                                                                                                                                28                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. A Effective shRNA-mediated knockdown of CRN2. Western blotting confirms a strong reduction 
(~95%) of the expression level of CRN2 in transduced U373 and A172 glioblastoma cell lines. Wild-type cells 
(U373 only), cells transduced with empty vector or a non-target shRNA-cassette (U373 and A172), as well as β-
actin staining,are given as controls. Immunofluorescence imaging of U373 glioblastoma cells fixed with 4% 
paraformaldehyde also indicates an overall decreased expression level of CRN2 in knockdown cells. The F-actin 
cytoskeleton seems not to be affected in CRN2 knockdown cells. The images showing lamellipodia in higher 
magnification are not enlarged areas from the images above, but from a different cell. CRN2 was detected by 
mAb K6-444, F-actin was stained with TRITC-phalloidin. Note the colour-coded fluorescence intensity signals 
(images with asterisk). Bars, 5 µm. 
 
 
 
 
 
 
 
 
 
Figure 19, continued. B. CRN2 knockdown inhibits invadopodia formation. Immunofluorescence imaging of 
invadopodia of a U373 glioblastoma cell. Glioblastoma cells grown on cover slips coated with FITC-gelatin 
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were fixed with 4% paraformaldehyde and stained with TRITC-phalloidin. One representative cell each is shown 
for knockdown and non-target control cells. Invadopodia at the ventral surface of the cell are defined by the 
presence of F-actin and absence of the matrix FITC-signal (arrows). Bars, 10 µm 
 
Immunofluorescence images of the CRN2 knockdown cells did not reveal any obvious 
changes in the F-actin staining, localization of the Arp2/3 complex and the morphology of 
lamellipodia. These structures appeared as in normal and non-target controls, although the 
CRN2-specific signal intensity (images with asterisk; note the colour code, yellow pixels 
versus dark red pixels) was reduced in virtually all knockdown cells (Fig 19A and data not 
shown). However, there were still low amounts of CRN2 in the knockdown cells, which 
exhibited a similar distribution as in non-target glioblastoma cells (Fig 19A). The signal 
intensity of cortical F-actin staining varied in both non-target and knockdown cells, and the F-
actin content remained unchanged in the CRN2 knockdown glioblastoma cells (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Knockdown of CRN2 inhibits cellular functions related to malignancy. A. CRN2 knockdown 
inhibits cell proliferation, but not cell cycle state. MTT-assay based proliferation rates of U373 and A172 
glioblastoma cells lacking CRN2 expression are compared to control cells; 100 independent experiments in 96-
well format each, Student’s t-test;U373, ∆OD595 0.001 versus 0.045, p = 2.7 × 10−12; A172, ∆OD595 0.14 versus 
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0.20, p = 1.0 × 10−10. Trypsination/replating based proliferation rates of U373 and A172 glioblastoma cells 
lacking CRN2 expression are compared to control cells; a certain number of cells were seeded and counted again 
after 2 days; four independent experiments each. Student’s t-test; U373, factor 2.2 versus 3.4, p = 0.005; A172, 
factor 1.4 versus 2.1, p = 0.012. PI-FACS analysis of cell cycle state of U373 and A172 CRN2 knockdown cells. 
Fixed cells were stained with propidium iodide and 10,000 single cells from three independent experiments were 
analysed by fluorescence-activated cell sorting (PI-FACS). The histograms demonstrate the fractions of cells in 
G0/1, G2/M and S phase; A, apoptosis. For control, cells treated for 16 h with a cdk4-inhibitor (Calbiochem, 
219476) are given. 
 
In contrast, multiple malignancy-related cellular functions were inhibited. Glioblastoma cells 
with reduced CRN2 levels exhibited an inhibition of the cell proliferation rate, as determined 
by two different assays, cell viability measurements (U373, −98%, p < 10−11; A172, −30%, p 
= 10−10) as well as trypsination/replating experiments (U373, −35%, p = 0.005; A172, −33%, 
p = 0.012) (Fig 20A). An analysis of the cell cycle state by PI-FACS did not indicate an 
inhibition of the cell cycle (Fig 20A). Monitoring single CRN2 knockdown glioblastoma 
cells, we determined a reduction of their ability to migrate compared to non-target shRNA 
control cells (U373, −62%, p < 10−6; A172, −54%, p < 10−8) (Fig 20B). 
 
Figure 20, continued. B. CRN2 knockdown inhibits cell migration and invasion. The single cell motility chart 
indicates the values from a total of 40 cells, each derived from several independent experiments; Student’s t-test: 
U373, velocity 5.36 µm/70 min versus 14.3 µm/70 min, p = 6.4 × 10−7; A172, velocity 5.0 µm/70 min versus 
10.9 µm/70 min, p = 9.3 × 10−9. The extracellular matrix (ECM) invasion rate graph shows one representative 
experiment with mean and standard deviation of 40 and 20 measurements of U373 and A172 glioblastoma cells, 
respectively; Student’s t-test: U373, 0.6 AFU versus 0.7 AFU, p = 0.016; A172, 0.7 AFU versus 0.9 AFU, p = 
6.9 × 10−5. Controls with 15 µM latrunculin B added to the cells in order to depolymerize the cellular F-actin 
demonstrate the maximum reduction of the invasion. Controls lacking the fluorescent dye showed background 
values of 0.2 AFU. For ECM invasion, see also Fig 19B. 
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In addition, we tested the ability of CRN2 knockdown glioblastoma cells to degrade and 
invade extracellular matrix (ECM). ECM invasion of CRN2 knockdown glioblastoma cells 
also exhibited a reduction (U373, −14%, p = 0.016; A172, −22%, p < 0.0001) (Fig 17B). To 
investigate the effects of the CRN2 knockdown on ECM invasion in more detail, we 
determined the overall activity of matrix metalloproteinases (MMPs). A172 cells lacking 
CRN2 exhibited a reduced activity of MMPs (−12%, p < 10−10), however, no difference was 
detectable for U373 cells (Fig 20C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 20, continued. C. CRN2 knockdown inhibits matrix metalloproteinase activity. A172 glioblastoma cells 
lacking CRN2 exhibit a reduced activity of secreted matrix metalloproteinases (MMP); however, such a 
difference was not detectable in U373 cells. Thirty measurements from six independent experiments each. 
Student’s t-test: U373, 14.4 AFU versus 14.5 AFU, p = 0.66; A172, 10.7 AFU versus 12.2 AFU, p = 1.4 × 10−11. 
Controls lacking the fluorescent substrate showed background values of 7 AFU 
 
We also visualized the formation of invadopodia in vitro (Fig 19B). Invadopodia are defined 
by co-localization of invadopodia markers, ie typical F-actin structures, with the degradation 
of fluorescently labelled extracellular matrix (Weaver, 2006). U373 non-target cells 
demonstrated a strong activity of matrix degradation on gelatin matrices, whereas in U373 
knockdown cells virtually no invadopodia were detected. For A172 cells, no invadopodia 
formation was found under our experimental conditions. Only two (gelatin, fibronectin) out of 
various components of the extracellular matrix have been used in the invadopodium assay, 
while the matrix metalloproteinase assay detected the overall activity of various, but not all 
known enzymatic activities. Thus, in both U373 and A172 knockdown, cell matrix 
degradation activities, although to different degrees, are inhibited upon reduction of CRN2 
levels. 
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4.0 Structural and functional diversity of novel CRN2 isoforms. 
4.1 Identification of three CRN2 proteins encoded by two mRNA species 
CRN2 usually migrates as a diffuse band of approximately 57 kDa. Immunoblotting of 
HEK293 and undifferentiated C2F3 cell lysates with the CRN2 specific monoclonal antibody 
K6-444 (Spoerl et al., 2002) revealed that the diffuse band can be separated into two closely 
migrating bands of 57/58 kDa (later referred to as CRN2i1/CRN2i2 (coronin-1C isoform 
1/isoform 2) (Fig.21A). Moreover, a second slower migrating protein of 60 kDa (later referred 
to as CRN2i3 (coronin-1C isoform 3) can be detected in murine skeletal muscle and 
differentiating C2F3 myoblasts as well as in brain and heart tissue (Fig.21A; figure 2B in 
reference (Spoerl et al., 2002). This protein is the only CRN2 isoform present in mature 
murine, bovine and human skeletal muscle tissue. 
 
 
 
 
 
 
 
Figure 21. A slower migrating isoform of CRN2 appears during myogenesis. A, lysates of HEK293 cells, 
murine skeletal muscle tissue, C2F3 myoblasts, and C2F3 myotubes (diff.) were analyzed by SDS-PAGE 
followed by western blotting using mAb K6-444 specific for CRN2 (Spoerl et al., 2002). B, 20 µg of total RNA 
from C2F3 myoblasts and 50 µg of total RNA from myotubes (diff.) were subjected to gel electrophoresis under 
denaturing conditions and analyzed by northern blotting using a full-length CRN2 cDNA as probe; for control, 
the ethidium bromide stained RNA-gel is shown. 
 
Northern blot analysis from total RNA of different murine organs, ES-cells, and 
undifferentiated C2F3 myoblasts employing a full-length CRN2 cDNA as a probe resulted in 
a single band of about 4.0 kb. Highest expression levels were detected in murine ES-cells as 
well as in thymus, testis, kidney, heart, and brain tissue (data not shown). Lung tissue and 
undifferentiated C2F3 myoblasts exhibited intermediate signal intensities. Lowest expression 
levels were detected in mature skeletal muscle and spleen tissue. During the differentiation 
process of C2F3 myoblasts the amount of CRN2 specific RNA levels decreased markedly 
(Fig. 21B). The possibility of posttranslational modifications of the CRN2 protein that could 
lead to differences in the apparent molecular mass was investigated by means of high 
resolution two-dimensional gel electrophoresis in conjunction with immunoblotting. 
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Ubiquitinylation and sumoylation (SUMO1-3) could not be detected in protein samples from 
murine, bovine and human skeletal muscle. Phosphorylations were present in CRN2; 
however, they did not contribute to the observed difference in the molecular mass (data not 
shown).  
Therefore, 5’-RACE, 5‘-RLM-RACE, and RT-PCR protocols were employed and resulted in 
the identification of additional transcripts. An alternative exon, exon 1b, contains two more 
start codons that are in frame with the known start codon of CRN2 (Fig. 22) potentially 
elongating the ‘conventional’ CRN2 transcript (referred to as isoform 1, CRN2v1, accession 
no. NM_014325) by addition of either 6 (referred to as isoform 2, CRN2v2, accession no. 
AM849477) or 53 codons (referred to as isoform 3, CRN2v3, accession no. AM849478). The 
longer isoform 3 encompasses the sequence of the shorter isoform 2. On the genomic level, 
the novel exon 1b is located within the previously proposed 30 kb intron 1 present between 
the 5’ untranslated exon, exon 1a, and the first coding exon, exon 2, of the ‘conventional’ 
CRN2 sequence. Sequence derived predictions suggest three potential CRN2 protein isoforms 
(Table.3), with molecular masses of 53 kDa and a pI of 6.7 (CRN2i1, NP_055140), 54 kDa 
and pI 6.9 (CRN2i2, AM849477), 59 kDa and pI 7.9 (CRN2i3, AM849478), that correspond 
to the protein bands detected by mAb K6-444. 
 
 
Isoforms of CRN2 due to different N-terminal extensions 
 
MYGPGSQLGKSGNNSWAKERGCSIACQGSLTSARLHAPSIGERPLSHMRWKDTMRRVVRQSKFRHVFG
QAVKNDQCYDDIRVSRVTWDSSFCAVNPRFVAIIIEASGGGAFLVLPLHKTGRIDKSYPTVCGHTGPV
LDIDWCPHNDQVIASGSEDCTVMVWQIPENGLTLSLTEPVVILEGHSKRVGIVAWHPTARNVLLSAGC
DNAIIIWNVGTGEALINLDDMHSDMIYNVSWNRNGSLICTASKDKKVRVIDPRKQEIVAEKEKAHEGA
RPMRAIFLADGNVFTTGFSRMSERQLALWNPKNMQEPIALHEMDTSNGVLLPFYDPDTSIIYLCGKGD
SSIRYFEITDESPYVHYLNTFSSKEPQRGMGYMPKRGLDVNKCEIARFFKLHERKCEPIIMTVPRKSD
LFQDDLYPDTAGPEAALEAEEWFEGKNADPILISLKHGYIPGKNRDLKVVKKNILDSKPTANKKCDLI
SIPKKTTDTASVQNEAKLDEILKEIKSIKDTICNQDERISKLEQQMAKIAA- 
 
CRN2i3 CRN2i2 CRN2i1 
 
Table 3. Isoforms of CRN2 due to different N-terminal extensions. Amino acid sequence derived predictions 
suggest three different proteins with molecular masses (kDa) and pI values of 53/6.7, 54/6.9, and 59/7.9, 
respectively. New symbols for protein (and mRNA), CRN2i1 (CRN2v1), CRN2i2 (CRN2v2) and CRN2i3 
(CRN2v3), according to (Morgan and Fernandez, 2008). 
 
 
  Results                                                                                                                                34                       
 
4.2 Evolutionary insight into CRN2 regulation 
Three atypical ESTs initiating from within 3' intron 1 were detected only from human coronin 
CRN2. Comparison of their common 5’ segment, up to 282 bp in gb:DC377708, with 39 
orthologous mammalian promoters identified a putative alternative exon 1b encoding the N-
termini of CRN2i2 and CRN2i3 in five catarrhine primates separated by less than 25 million 
years of evolution (viz. human, chimpanzee, gorilla, orangutan and gibbon). All earlier 
diverging primates (i.e. macaque, baboon, marmoset, tarsier, lemur and galago) and other 
mammals (eutherian, metatherian and prototherian) harboured either start codon mutations, 
frame shift deletions or splice site changes in their genomic sequences that precluded the 
generation of transcripts encoding CRN2i3. Only 3 of 11 primates (macaque, baboon and 
galago) and 6 of 19 other mammals (tree shrew, dog, horse, alpaca, rabbit and pika) retained 
the capacity to generate transcripts encoding the shorter CRN2i2. 
 
 
Figure 22. Promoter and exon-intron architecture of 5’ CRN2. A, the current reference assembly for CRN2 
(NC_000012.10) was characterized for repetitive elements, CpG composition, transcription start site(s) in dbTSS 
and known exon splice sites.  
 
A single promoter with a primary transcription start site (TSS) was detected in CRN2 exon 1a 
(Fig.22A). Sequence conservation of the core promoter among mammals established the 
functional importance of this region and highlighted several sequence motifs relevant to both 
general and specific transcriptional regulation. A profile hidden Markov model (pHMM) logo 
of the aligned sequences (Fig.22B) illustrates the manner by which “phylogenetic 
footprinting” can localize evolutionary functional constraint through column height (i.e. 
probability of occurrence) and nucleotide frequencies. Myogenic regulatory factors such as 
MyoD, Myf5, MRF4 and myogenin are known to control muscle-specific gene expression by 
forming hetero-dimers with E-proteins that bind E-box motifs (e.g. CACCTG) with candidate 
sites located in the CRN2 promoter region. Evolutionary analyses using the VISTA browser 
and rVISTA (Loots et al., 2002) identified other conserved, functionally relevant regulatory 
elements, including double representation of a prominent and strategically located motif 
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UF1H3beta_Q6. This DNA element (TGCGGGGGAGGGGC or CGCGGGGGCGGGGC) 
contains internal subsites for NGFIC (EGF4), Klf4 and Sp1 (common to many core promoters 
defined by CpG islands) with conspicuous G-rich stretches. This may bear directly on MyoD 
regulation of CRN2 transcription as recent evidence identifies guanine-rich quadruplex 
structures of regulatory sequences as key binding elements for homodimeric MyoD (Yafe et 
al., 2008). 
 
Figure 22, continued. B, promoter sequences from -300 to +100 bp for CRN2 were aligned, converted to an 
HMM model and visualized as a sequence logo representing 12 mammalian species (i.e. human, orangutan, 
marmoset, macaque, cow, pig, vampire bat, guinea pig, mouse, rat, dog and opossum). The transcription start site 
(TSS) was designated by genomic mapping of external database CAGE, EST and full-length cDNA tags. 
Conserved motifs in the core promoter were characterized by phylogenetic footprinting programs, which 
identified the doubly represented element UF1H3beta_Q6.  
 
The region between the upstream promoter and coding exon 2 was also subjected to 
comparative genomic analysis to investigate the origin of an alternative transcription start site 
near the 3’ end on intron 1 (Fig.22C). The genomic sequence capability was restricted to 
modern primates and the most 5’ of three human ESTs came to within 36 bp of a well-
conserved CAG motif, possibly reflecting the true end of intron 1a and a novel splice site 
demarcating alternative exon 1b of 291-317 bp in these primates. 
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Figure 22, continued. C, the alternatively spliced region is shown as a genomic DNA sequence logo derived 
from 11 primates capable of generating transcripts for both isoforms 2 and 3 (human, chimp, orangutan, gibbon), 
isoform 2 only (macaque, baboon, galago, tree shrew) or neither (marmoset, lemur, tarsier). Three human ESTs 
encoded by exon 1b giving rise to protein isoforms 2 and 3 are preceded by a putative, alternative intron 1a 
splice site. 
4.3 CRN2i3 is part of the myogenic differentiation program 
While the ubiquitous CRN2i1/2 (“diffuse” band) appears to be expressed constitutively, 
expression of the largest isoform CRN2i3 is specifically up-regulated during myogenic 
differentiation. In contrast to undifferentiated C2F3 myoblasts, differentiated C2F3 myotubes 
(eight days of differentiation) display mostly CRN2i3, with only a trace of isoforms 1 and 2 
(Fig. 21A). We monitored the switch from the faster to the slower migrating isoforms by a 
time course experiment of differentiating C2F3 cells. At day 0, before induction of 
differentiation, CRN2i1 and 2 were detected in the C2F3 myoblasts. Low amounts of CRN2i3 
were observed after three days of differentiation, with a wide and diffusely migrating band 
corresponding to CRN2i1 and 2 below a thin band of CRN2i3 (Fig.23A). Detection of 
annexin A7 was used as control, since the large isoform of annexin A7 (51 kDa) is a marker 
of late (in vitro) myogenesis and also appeared at day three (Clemen et al., 1999). CRN2i3 
was exclusively found in mature skeletal muscle (see below). To validate the specificity of 
CRN2i3 in the myogenic differentiation program, we converted NIH3T3 fibroblasts, which 
only express the CRN2i1 and 2, into myogenic cells by ectopic expression of MyoD (Clemen 
et al., 1999). Converted cells initiated expression of CRN2i3 (Fig.23B). Similarly, MyoD 
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expression in C2F3 cells grown under non-differentiating conditions led to an expression of 
CRN2i3. 
 
 
 
 
 
 
 
 
Figure 23. A. Time course of differentiation of C2F3 myoblasts. Cells were harvested at the indicated time 
points (day after initiation of differentiation) and analyzed by immunoblotting using mAb K6-444 and mAb 203-
217 specific for annexin A7 as a control of myogenic differentiation. B. myogenic conversion of NIH3T3 
fibroblasts using a retroviral vector encoding human MyoD. CRN2 from hMyoD-transduced and untransduced 
NIH3T3 and hMyoD-transduced, differentiated and undifferentiated C2F3 myoblasts is shown. Cells were 
harvested four days after transduction or after five days of differentiation, and analyzed by SDS-PAGE followed 
by western blotting using the CRN2 and annexin A7 specific antibodies. 
4.4 Different oligomerization state of the CRN2 isoforms 
Sucrose gradient fractionation of lysates of differentiated C2F3 myotubes demonstrates a co-
distribution of the three CRN2 isoforms (Fig.24). They were present in fractions of low 
density (fractions 4-9) that contained part of the membrane-associated cortical F-actin as well 
as Golgi membranes (β-COP staining). 
 
 
 
 
 
 
 
 
 
 
Figure 24. Identical subcellular localization of CRN2 isoforms. A, Fractionation of cell lysates from 
differentiated C2F3 myotubes by sucrose gradient centrifugation. Fractions were collected and analyzed by SDS-
PAGE followed by western blotting using the antibodies K6-444 (CRN2), mAb AC 40 (β-actin; Sigma), anti-
BiP/GRP 78 (Transduction Laboratories), and maD (β -COP (Pepperkok et al., 1993)). Arrow heads indicate the 
position of the slower migrating isoform 3. 
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A second pool of CRN2 was detected in fractions 15-18 that contain heavy membranes like 
ER-membranes indicated by the presence of BiP/GRP78. CRN2 (isoform 1) like other short 
coronin proteins forms homo-trimers. Oligomerization is mediated by the C-terminal coiled 
coil domain (Kammerer et al., 2005; McArdle and Hofmann, 2008; Rybakin and Clemen, 
2005) Gel filtration analysis of soluble fractions derived from murine kidney and skeletal 
muscle tissue indicates that CRN2i1/2 of kidney is mainly present in fractions corresponding 
to a molecular mass of 180 kDa, indicating the presence of at least a part of CRN2 in a 
trimeric state. In contrast, CRN2i3 derived from skeletal muscle is present mostly in fractions 
of approx. 60 kDa, corresponding to a monomer (Fig. 25). 
 
 
 
 
 
 
 
 
 
 
Figure 25. Gel filtration analysis of cytoskeletal protein extracts (100,000 g supernatant) of murine kidney and 
skeletal muscle tissue using a Superdex G200 column. Fractions were collected and analyzed by SDS-PAGE 
followed by western blotting using mAb K6-444, mAb AC 40, and mAb 5C5 (sarcomeric-actin; Sigma). The 
molecular mass is given. 
4.5 Structural models of CRN2 isoforms 
Following the typical topology of WD40 repeat proteins, in which the first β-strand of a blade 
is provided by the last β-strand of the preceding WD40-repeat (Hudson and Cooley, 2008; 
Smith, 2008). The N-terminal β- strand formed by residues 17-22 in CRN4 provides the first 
β-strand of the last propeller blade of the protein (Fig.25). Therefore, we suggest that in 
CRN2i3, which harbors an N-terminal 53 amino acid extension, residues 69-74 map onto this 
motif of CRN4, thus aligning residues 66-402 of CRN2i3 with the seven-bladed β propeller 
fold (Fig. 25).  
Using PSIPRED (McGuffin et al., 2000) the additional amino acid sequence in CRN2i2 (aa 1-
6) and CRN2i3 (aa 1-53) was predicted to consist of one (isoform 2) or three (isoform 3) β-
strands (Fig.25). It is highly unlikely that the additional peptide will form an eighth blade 
within the β-propeller. We rather suggest that the additional β-strands either form an 
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independent domain or they interact with accessible secondary structure elements of the 'core' 
protein, for example by annealing to existing β-strands.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  Structure-based sequence alignment of CRN2 with CRN4. The CRN4 amino acid sequence is 
sectioned according to the fold observed in the crystal structure (Appleton et al., 2006). The amino acid 
sequences of all three isoforms of CRN2 are aligned with CRN4 using amino acid sequence similarity and 
predicted secondary structure elements. The secondary structure of CRN2 was predicted using PsiPred (Bryson 
et al., 2005) and is annotated in the lines shown as 'pred' (H: helix, E: strand, C: coil). The first amino acids of 
CRN2i1, CRN2i2 and CRN2i3 are indicated. The motifs printed in bold are similar to the heptad repeat motifs 
found in coiled coils. Potential phosphorylation sites in the N-terminal region of CRN2 are underlined.  
 
Based on the three-dimensional structure of CRN2, in which the N- and C-termini of the 
coronin β propeller are in spatial vicinity (Fig.26; aa 7-400 of CRN2i1 are visualized), the 
additional secondary structure elements at the N-terminus may interact with a β-strand in the 
C-terminal extension or with residues of the coiled coil domain, and thus interfere with 
oligomerization. 
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Figure  26. Homology model of CRN2 β propeller and C-terminal extension domains. The homology model 
of CRN2 (isoform 1; aa 7-400) was generated as reported earlier (Rosentreter et al., 2007). The N-terminal 
region is colored blue, the WD40 repeat domain (β propeller domain) is shown in aqua, and the C-terminal 
extension domain is shown in brown. Additional amino acids of isoforms 2 and 3 are fused to the N-terminal 
region and, in the case of isoform 3, can possibly extend to interact with the C-terminal extension domain and/or 
the coiled coil domain.  
4.6 GFP-fusion proteins of CRN2 isoforms localize to F-actin structures 
The three isoforms of CRN2 were expressed as GFP-fusion proteins and their distribution was 
studied in HEK293 cells and in undifferentiated C2F3 myoblasts and differentiated C2F3 
myotubes. Expression of the fusion proteins was confirmed by western blotting. C2F3 
myotubes expressing CRN2i1 or CRN2i2 additionally displayed the endogenous CRN2i3 
(data not shown). In general, all isoforms localized in a diffuse and punctuated manner in the 
cytosol (Fig.27 A-C, arrows), at the leading edges of lamellipodia and filopodia (double-
arrows), at the submembranous area (arrowheads), and to F-actin fibers (double-arrowheads). 
In C2F3 myotubes the GFP-fusion proteins mainly localized to F-actin fibers. CRN2 was 
highly enriched in F-actin rich areas, with high signal intensities of CRN2 matching high 
signal intensities of F-actin. Significant differences of the CRN2 isoforms with regard to F- 
actin association or contribution to cellular function could not be observed as assessed by 
differential centrifugation and cell motility assays (data not shown). 
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Figure 27. Subcellular localization of CRN2 isoforms expressed as GFP-fusion proteins. A, undifferentiated 
C2F3 myoblasts expressing EGFP-CRN2i1; B, HEK293 cells expressing EGFP-CRN2i2, C, differentiated C2F3 
myotubes expressing EGFP-CRN2i3. Cells were fixed with formaldehyde. Green- fluorescence signal of EGFP-
fused CRN2 isoforms,  red- F-actin staining with TRITC-phalloidin. Arrowhead, submembranous localization; 
double-arrow, lamellipodial and filopodial enrichments of CRN2; arrow, dot-like structures at the bottom of the 
cell; double-arrowhead, localization of CRN2 to actin fibers. 
4.7 CRN2 is a novel component of podosomes 
Immunoblotting of podosome-enriched cell fractions from primary human macrophages 
indicated expression and potential podosomal localization of CRN2i1/2 (Fig.28A). 
Immunofluorescence images using mAb K6-444 confirmed endogenous CRN2 as a novel 
component of podosomes (Fig.28B). A comparable distribution of CRN2 proteins was seen in 
macrophages transfected with constructs encoding isoforms 1, 2, and 3 fused to GFP (Fig. 
28C; only CRN2i1 is shown). Every podosome displayed an enrichment of CRN2 within the 
F-actin-rich core structure (arrows). In addition, CRN2 co-localized to submembranous F-
actin structures of macrophages (Fig.28D, arrowheads). 
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Figure 28. CRN2 is a component of podosomes. A, fractions of human primary macrophages enriched in 
podosomes, bovine skeletal muscle tissue, control fractions devoid of podosomes (Gringel et al., 2006), C2F3 
myotubes, macrophages, and 10T1/2 fibroblasts were analyzed by SDS-PAGE followed by western blotting 
using mAb K6- 444 specific for CRN2. B, confocal images demonstrate an enrichment of endogenous CRN2 at 
podosomes of primary human macrophages, fixed with formaldehyde and stained with mAb K6-444.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 continued C, Primary human macrophages transfected with EGFP-fused CRN2i1. D, Enlarged view 
of a GFP-CRN2i1 positive human primary macrophage. Arrow, localization of CRN2 in podosomes; arrowhead, 
submembranous enrichment of CRN2.  
 
To address the question whether CRN2 is essential for the formation of podosomes a pool of 
CRN2-specific siRNAs was transfected into primary human macrophages. In contrast to cells 
transfected with a control (scrambled) siRNA, a significant reduction of the CRN2 protein 
started three days after transfection (Fig.29). Immunofluorescence images of macrophages 
still expressing (day 1 after transfection) and completely lacking endogenous CRN2 (day four 
after transfection) demonstrate normal podosomes (data not shown). CRN2 knockdown 
neither did influence number, size, and distribution nor fluorescence intensity of podosomes. 
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Figure 29. CRN2 knockdown human in macrophages. Effective siRNA-mediated knockdown of CRN2 in 
human macrophages. Western blotting confirms a strong reduction in the expression level, three days after 
transfection, and no CRN2 is detectable at four days. β-actin staining used as control.  
4.8 CRN2i3 is a structural component of neuromuscular junctions and myofibrils 
Based on our observation that mature skeletal muscle fibers exclusively express CRN2i3, 
transverse sections of human skeletal muscle were immunolabelled with mAb K6-444. In 
general, the antibody showed a relatively uniform distribution throughout the muscle fibres 
(data not shown). However, in a subset of muscle fibers, subsarcolemmal enrichments of 
CRN2 were visible. Co-staining with FITC-labelled α-bungarotoxin demonstrated that these 
areas correspond to the postsynaptic area and the junctional sarcoplasm of motor end-plates 
(Fig.30, arrow). Longitudinal optic sections of single human muscle fibers labelled with 
CRN2 mAb revealed a striated CRN2 staining pattern. Co-stainings with an antibody against 
the M-band component myomesin (Fig.31A) and an antibody against actin (Fig.31B) showed 
that CRN2i3 is a component of the thin-filament of myofibrils (Fig.31, 32). 
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Figure 30. CRN2i3 co-localizes with the motor end plate. Immunostaining for endogenous CRN2 in 
transversal cryosections of mature human skeletal muscle frequently indicates subsarcolemmal enrichments. 
Double stainings with FITC-labelled α-bungarotoxin indicate a co-localization of CRN2 at postsynaptic area and 
the junctional sarcoplasm of the motor end plate (arrow). Note that the intensity of CRN2-staining as well as 
background levels in both channels differ from normal staining procedures by the lack of fixation to preserve α-
bungarotoxin reactivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. CRN2i3 targets to thin filaments of myofibrils. Human myofibers were isolated, double-labelled, 
and images were taken by confocal microscopy. A, co-staining with myomesin antibody indicates a gap (arrows) 
between CRN2 and the M-band. B, co-staining with actin antibody demonstrates a specific co-localization of 
CRN2 with sarcomeric actin. 
 
CRN2 bungarotoxin merge
50 µm
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Figure 32. Cartoon represents CRN2i3 localization at the sarcomeric actin filaments. Here a longitudinal 
section of muscle fibre is shown. Components of sacomeric unit, such as thick filament composed of myosin 
(highlighted in blue color) and thin filaments primary composed of actin filaments (highlighted in dark green 
color) are displayed. The components of each thin filament subunit which comprise of actin, topomyosins, 
topinins, nibulin filaments are shown. The co-localization of CRN2i3 to the specific regions of F-actin of the thin 
filament of a sarcomere is shown in light green color. CRN2i3 seem to be involved in bundling and crosslinking 
of these sarcomeric actin filaments. Other regions of sacromere like Z-band (in the form a zip zag triple lines 
composed of α-actinin) M-band (transparent region) are also shown.  
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5.0 Influence of phosphorylation on structure and function of CRN2 
5.1 Posttranslational modifications of CRN2 
In order to evaluate the potential of posttranslational modifications on structure and function 
of CRN2, the complete amino acid sequence of CRN2 was subjected to in silico analyses. A 
number of posttranslational modifications were predicted in the CRN2 protein as shown in 
(Fig 33). One of the residues of particular interest was Ser463 of the coiled coil domain, 
which is a predicted phosphorylation site. Structural modelling indicates that phosphorylation 
of Ser463 residue of CRN2 will result in disruption of the CRN2 trimer (Hofmann and 
Clemen, unpublished). 
 
 
 
Figure 33. Predicted posttranslational modifications of CRN2, Post-translational modifications of the CRN2 
protein predicted with high probability scores; N, N-glycosylation; O, O-ß-GlcNAc addition; P, tyrosine 
phosphorylation; P, serine phosphorylation; S, sulfation; U, sumoylation. Surface exposed residues are 
highlighted in light green, surface accessible residues in light blue. 
5.2 CRN2 interacts with actin cytoskeleton regulator CK2α kinase  
Further in silico analyses indicated that CRN2 residue Ser463 is part of a potential CK2α 
binding motif. CK2 is a pleiotropic, constitutively active, heterotetremeric protein with two α 
and two β units (Allende and Allende, 1995; Guerra et al., 1999). It is well characterized as 
one of the actin cytoskeleton regulators. It phosphorylates VCA domain of WASP, which in 
turn enhances the interaction of VCA domain with the Arp2/3 complex and thereby increases 
Arp2/3 mediated actin polymerization (Canton and Litchfield, 2006). To examine the putative 
interaction of CK2α and CRN2, we conducted pulldown assays using recombinant GST–
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CK2α together with His6-CRN2 wild-type or S463D mutant peptides (aa 300-474) as well as 
together with GFP-CRN2 wild-type or S463D mutant (full-length CRN2). GST–CK2α firmly 
interacted with both wild-type as well as phosphomimetic CRN2 peptides without any notable 
difference in binding (Fig 34A). Comparatively, in case of full-length CRN2 the GFP-CRN2 
wild-type interaction was much stronger than the S463D mutant. (Fig 34B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. CRN2 interacts with CK2α. A, pulldown assay employing full length CK2α and C-terminal 
peptides of CRN2. Cell lysates for input: E. coli expressing His6-tagged wild-type CRN2_aa300-474 and mutant 
CRN2_300-474_S463D (30 kDa). Recombinant proteins bound to glutathione-coated beads: GST-CK2α, GST-
CK2α dead, GST; and blank beads. B, pulldown assay employing full length CK2α and full length CRN2. Cell 
lysates for input: HEK293 cells, which express endogenous CRN2 (57 kDa), stably transfected with constructs 
coding for GFP-CRN2, GFP-CRN2_S463D (82 kDa), and GFP (27 kDa). Recombinant proteins bound to 
glutathione-coated beads: GST-CK2α, GST-CK2α dead, GST; and blank beads. After incubation with the cell 
lysates, beads were washed and mixed with SDS sample buffer. CRN2 was visualized by western blotting using 
mAb K6-444. 
5.3 In vivo phosphorylation of CRN2 
Two-dimensional gel electrophoresis in conjunction with immunoblotting revealed several 
distinct spots of CRN2 in the murine brain and heart, but only a single or two spots were 
detectable in case of murine as well as human skeletal muscle. Treatment of the protein 
samples with alkaline phosphatase resulted in a shift of all spots observed to a more alkaline 
pI (Fig. 35A and data not shown). To confirm a phosphorylation we used a mixture of native 
and dephosphorylated samples resulting in two spots of the same relative positions (Fig. 35A, 
bottom panel). The apparent difference between spots of phosphorylated and 
dephosphorylated CRN2 is 0.5 pH degrees and in theory corresponds well to a loss of three 
phosphate residues.  
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We further tried to screen CRN2 for other predicted posttranslational modifications by high-
resolution two-dimensional gel electrophoresis combined with mass spectrometry, but a direct 
analysis failed due to limited protein expression levels. However, high-resolution two-
dimensional gel electrophoresis of samples of human skeletal muscle tissue in conjunction 
with immunoblotting demonstrated that none of the signal spots obtained for ubiquitin or 
SUMO1-3 could be merged to the signals of CRN2 (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Presence of a phosphorylated pool of CRN2. Lysates of murine brain and skeletal muscle tissue 
were separated by 2D-gel electrophoresis. CRN2 was visualized by western blotting using mAb K6-444. The 
upper panel presents the untreated, the lower panel the sample of CRN2 which was dephosphorylated in vitro, 
respectively. As a control, the third panel of murine skeletal muscle additionally shows a mixture of both, the 
untreated and in vitro dephosphorylated samples, resulting in two separated CRN2 spots. 
5.4 In vitro phosphorlyation of CRN2 by CK2α kinase 
The stable interaction between CK2α kinase and CRN2 further lead to reason, whether these 
interactions result in favourable phosphorylation of CRN2. To address this, His-tagged wild-
type and S463D and S463A mutant CRN2 peptides (aa 300-474) from E.coli as well as GST-
tagged CRN2 full-length proteins from SF9 cells were used. The purified CRN2 proteins were 
incubated with GST-CK2α kinase or a kinase dead control. Reactions were analysed by SDS-
PAGE followed by autoradiography. CK2α kinase steadily phosphorylated the CRN2 wild-
type peptide, but such signals were undetected with phosphomutant CRN2 S463A and S463D 
peptides (Fig 35A). Similar results, however with weaker signal intensity, were obtained from 
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the full-length CRN2 proteins (Fig 36B). Protein samples loading control are shown with 
representative coomassie gels (Fig 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  36. CRN2 is a target of CK2α. A, In vitro kinase assay employing full length recombinant GST-CK2α  
(66 kDa, arrow) and His6-tagged C-terminal peptides of CRN2 (30 kDa, arrowhead). Time course (30, 60, 90 
minutes) of α 32ATP incorporation into wild-type CRN2_aa300-474, and mutant S463D and S463A peptides. 
Controls where the CRN2 peptide, α32ATP, or CK2α were omitted, and use of a kinase-dead CK2α are indicated. 
Upper panel 32P , autoradiogram of phosphorylation of CRN2 and auto-phosphorylation of CK2α. Lower panel, 
the corresponding Coomassie brilliant blue stained gel. Asterisk, recombinant CRN2 peptides contaminated by 
an E. coli chaperone (PMF identification was done). Note that the phosphorylation levels of the mutant peptides 
after 90 min are strongly reduced and that the mutant peptides inhibit the activity of CK2α (mix). B, In vitro 
kinase assay employing full length recombinant GST-CK2α (66 kDa, arrow) and GST-His6-tagged full length 
CRN2 (90 kDa, arrowhead). Time course (1, 5, 10, 30, 120 minutes) of α32ATP incorporation into wild-type and 
S463D-mutant CRN2. Controls where CRN2, α32ATP, or CK2α were omitted, and use of a kinase-dead CK2α 
are indicated. Upper panel 32P , autoradiogram of phosphorylation of CRN2 and auto-phosphorylation of CK2α. 
Lower panel, the corresponding Coomassie brilliant blue stained gel. Note that after longer incubation time 
similar phosphorylation levels of wild-type and mutant full length CRN2 are visible. 
5.5 Phosphorylation of Ser463 regulates oligomerisation of CRN2 
Wild-type as well as phosphomimetic S463D and non-phosphorylateable S463A mutant 
CRN2 peptides (aa 300-474aa) were subjected to gel filtration experiments followed by SDS-
PAGE and western blotting. We observed a notable change in the oligomerisation state of 
CRN2 S463D. The two wild-type and S463A peptides formed trimers (81kDa), whereas 
phosphomimetic CRN2 S463D eluted as a dimer (Fig.37). These observations well agree with 
our results from in silico modelling studies, in which phosphorylation of Ser463 were 
predicted to lead to a dimeric coiled coil domain. However, changes of the oligomerization 
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state could neither be observed in the GFP- nor GST-tagged full-length CRN2 S463D 
phophomietic mutant (data not shown). 
 
                 
 
 
 
 
 
 
 
 
 
 
Figure  37. S463D phosphomimetic mutation of CRN2 abolishes trimerization. A. Gel filtration analysis of 
purified recombinant wild-type as well as S463A and S463D mutants of C-terminal CRN2 peptides mimicking 
non-phosphorylated and phosphorylated states respectively using a Superdex G75 column (monomers: 22 kDa 
calculated, 27 kDa apparent molecular weight). As predicted from structural data analysis phosphorylation 
mutant S463D clearly indicates the formation of dimers instead of trimers. All fractions were collected and 
analyzed by SDS-PAGE followed by western blotting using antibody K6-444.  
 
 
5.6 Phosphomimetic S463D mutant CRN2 inhibits actin polymerisation 
Previously, we have demonstrated that CRN2 interacts with the Arp2/3 complex (Rosentreter 
et al., 2007). This led us to further dissect the role of CRN2 on Arp2/3-mediated actin 
polymerization. We engaged both wild-type and phosphomimetic S463D CRN2 peptides 
(aa 300-474) in an Arp2/3 mediated actin polymerization assay. Actin polymerization in 
presence of Arp2/3 complex and its activator N-WASP-VCA domain significantly reduced 
after addition of CRN2. CRN2 was added in two different concentrations, 1x (0.8µM) and 2x 
(1.6µM), which showed a dose-dependent inhibitory effect. Moreover, compared to wild-type 
CRN2, phosphomimetic S463D CRN2 executed a significantly higher inhibitory effect on 
Arp2/3-mediated actin polymerisation (Fig.38). 
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Figure 38. CRN2 wild-type and S463D mutant peptides exhibit different inhibitory effects on Arp2/3 
mediated actin polymerisation. Bar graph represents the mean maximal slope of actin polymerization 
calculated from 50 independent experiments normalized to G-actin/Arp2/3 (first bar = 1.0). Concentrations of 
CRN2-1x (0.8µM) and 2x (1.6µM). Control reactions with and without WASP-VCA domain protein are shown. 
p values indicate statistically significant inhibitions of the Arp2/3 mediated actin polymerisation in the presence 
of CRN2. 
5.7 Phosphomimetic S463D mutant of CRN2 suppresses migration 
To determine the biological implication of CRN2 phosphorylation, confluent monolayers of 
HEK293 cells stably expressing GFP-CRN2 wild-type as well as S463A and S463D mutants 
were used for in vitro wound healing assays. Wound closure was monitored over a period of 
7hrs. A statistically considerable reduced velocity in wound closure was measured in case of 
CRN2 S463D phosphomimetic mutant (22.9 µm/h versus 28.9 µm/h and 27.6 µm/h for wild-
type and S463A, respectively) (Fig 39).  
 
 
 
 
 
 
 
 
 
Figure 39. CRN2 S463D mutation inhibits wound closure in vitro. See text for details; number of 
experiments: 60; Student’s t-test p<0.05 is significant. 
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5.8 Phosphomimetic S463D mutant CRN2 hinders formation of cellular protrusions 
HEK293 cells stably expressing GFP-CRN2 wild-type as well as S463D and S463A mutants 
were further used to investigate the formation of cellular protrusions. Cells were monitored 
for formation of cellular protrusions over a period of 30mins. In comparison to HEK293 cells 
expressing wild-type CRN2 or the S463A mutant, cells with the CRN2 S463D 
phosphomimetic mutant demonstrated a significantly hindered formation of cellular 
protrusions by producing only half the number of cell protrusions (Fig 40 A, B).                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. CRN2 S463D mutation suppresses the formation of cellular extensions. A, CRN2 versus CRN2-
S463D: mean no. of cellular protrusions 6.0 / 2.8, standard deviation 2.1 / 2.2, number of measurements 90 / 90, 
Student’s t-test p = 4x10-19, statistically significant difference. B, CRN2 versus CRN2-S463A: mean no. of 
cellular protrusions 4.9 / 5.0, standard deviation 1.5 / 1.9 number of measurements 90 / 90, Student’s t-test 
p = 0.73, no statistically significant difference. 
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III. Discussion 
6.0 Role of CRN2 in cellular processes 
Until now biochemical or biological properties of only few coronin proteins have been 
characterized in detail within different species (for review see (Clemen et al., 2008). We 
previously identified CRN2 as an actin filament crosslinking and bundling protein in vitro 
(Spoerl et al., 2002) and described its expression and distribution pattern in the developing 
murine brain (Hasse et al., 2005). In these studies, we address biological functions of CRN2 
in mammalian cells. 
6.1 Structural properties of CRN2 
Until a crystal structure of CRN4 became available (Appleton et al., 2006), CRN2 was 
thought to consist of a N-terminal domain (aa 1–71) with a coronin-specific signature motif 
(aa 1–11), a core region containing five predicted WD40-repeats (aa 72–299), and a C-
terminal domain (aa 300–474) with a very C-terminal-coiled coil motif (aa 444–474) (Ref. 
Rosentreter). Based on the X-ray structure of CRN4, our structural homology model of CRN2 
indicates that CRN2 also forms a seven-bladed WD40-repeat beta-propeller. The two 
additional WD40-repeats do not have the canonical WD motif, but this is also observed in 
other WD40 propellers. The structural attributes, stabilizing intramolecular interactions of 
domains, and functional implications described for CRN4 can be assigned to CRN2 too. In 
specific, surface areas of CRN4 that in silico interact with F-actin, can as well be assigned to 
CRN2 . F-actin binding of CRN4 was mapped to a short stretch of positively charged amino 
acids (aa 400–416, KSRELRVNRGLDSARRR) within the C terminus preceding the coiled 
coil. This stretch of positively charged amino acids is conserved in CRN2 (aa 398–419, 
KNRDLKVVKKNILDSKPTANKK). 
6.2 CRN2 regulates F-actin dependent processes  
We analyzed the role of CRN2 in various F-actin dependent cellular processes. In wound 
healing assays the exclusive presence or lack of the five central WD40-repeats strongly 
inhibited wound closure. These effects and the fact that CRN2 localizes to the cellular cortex 
prompted us to broaden our investigation with more emphasis on cell proliferation, 
cytokinesis and cell activity. Based on our data we may define different types of effects 
induced by the expression of the CRN2 peptides. CRN2 peptides containing WD-repeats and 
lacking F-actin binding sites (CRN2WD, CRN2∆NC) generally resulted in major inhibitory 
influence on wound healing and cellular protrusions. They most likely act indirectly by 
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dominant negative effects, as these ectopically expressed WD-repeats could compete for 
binding partners of the endogenous CRN2. CRN2 peptides comprising the F-actin binding 
domains but lacking the central WD-repeats (CRN2NC, CRN2NGC) most likely act directly  
on F-actin by their intrinsic F-actin bundling and crosslinking activity. Their effects could rise 
by that they act without a specific regulation via putative binding partners of the WD-
propeller platform. Slight changes in cellular functions are obtained when full-length CRN2 
(NWDC) is overexpressed, although these cells demonstrated an increased number of small 
filopodia-like extensions. Effective knock down of CRN2 by RNAi finally showed a strong 
inhibition of cellular migration, but lacked a significant change in the overall structure of the 
F-actin cytoskeleton.  
This complex situation may be resolved by studies on interactions of CRN2 with other 
proteins. These interactions may vary locally at distinct cellular compartments to specifically 
regulate the formation and maintenance of different types of actin filaments. To date, there is 
no evidence that CRN2 acts independent of F-actin or that CRN2 is involved in vesicle 
trafficking as described for CRN7 and other long coronins (Rybakin and Clemen, 2005). In 
the light of growing reports on coronin protein interactions, two major mechanisms appear 
that involve the Arp2/3 complex and cofilin. In this context, it is noteworthy that we were 
able to co-immunoprecipitate cofilin and p34 in complex with CRN2. Yeast CRN11 was 
found to directly associate with the Arp2/3 complex, most likely via the Arc35 subunit, and 
exhibits an inhibitory function on the actin nucleation activity of the Arp2/3 complex 
(Humphries et al., 2002; Rodal et al., 2005). The Arc35 binding motif is located in the coiled 
coil region of yeast CRN11. Consistent with this observation C-terminally truncated murine 
CRN4 did not bind to the Arp2/3 complex (Appleton et al., 2006). Likewise, mammalian 
CRN1 was shown to bind to the p34 subunit of the Arp2/3 complex ((Kalil and Dent, 2005; 
Kammerer et al., 2005; Pollard and Borisy, 2003). CRN1 interaction with Arp2/3 complex 
was demonstrated to be regulated by protein kinase C (PKC) mediated phosphorylation (Cai 
et al., 2005). Likewise, an inhibitory function of CRN2 on the Arp2/3 complex would provide 
an explanation for some of our functional results. Indeed, we could show that CRN2 inhibits 
actin polymerization in vitro (see below).  
Cofilins emerge as key regulators of axonal growth cone dynamics. The central region of the 
growth cone contains a Factin meshwork as well as F-actin bundles playing a central role in 
motility (Kalil and Dent, 2005; Kammerer et al., 2005; Pollard and Borisy, 2003). The 
severing activity of cofilins is regulated by LIM kinases, slingshot phosphatases, and their 
upstream effectors (Gungabissoon and Bamburg, 2003). Moreover, cofilin can act 
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synergistically with the Arp2/3 complex to amplify local actin polymerization in lamellipods 
(DesMarais et al., 2005; DesMarais et al., 2004). Although not investigated yet, CRN2 could 
play a regulatory role in this cofilin-dependent F-actin turnover process as well. Yeast CRN11 
interacts and synergizes with cofilin and accelerates the actin turnover via its WD40-repeat 
domain (Gandhi and Goode, 2008b). Mammalian CRN1 was shown to direct Slingshot 
phosphatase (SSH1L) to lamellipodia, where this (SSH1L) were shown to regulate cofilin 
activity via effective dephosphorylation  (Cai et al., 2007b). Moreover (Brieher et al., 2006) 
proposed an experimentally based model of interactions between CRN4, cofilin, and Aip1. 
All three proteins synergistically led to a disassembly of F-actin structures. In this model 
CRN4 bound to F-actin promotes cofilin and subsequently Aip1-binding to the actin filament 
triggers its fast disassembly. 
6.3 Influence of phosphorylation on structure and function of CRN2 
Conventional short coronins like CRN2 are found to posses a fourfold repeat of the 
characteristic coiled coil hepta-peptide sequence at their C-terminal extension. This coiled 
coil domain is predicted to be actively involved in homo-trimers (McArdle and Hofmann, 
2008). Contribution of this salient coiled coil domain towards the regulation of these proteins 
functions has been topic of speculation in recent years. Therefore we investigated this domain 
by in silico analysis and examined for posttranslational modification sites. This drew our 
attention to serine 463 residue found in this domain, whose phosphorylation might influence 
the oligomerisation state. This was confirmed by gel filtration studies using C-terminal CRN2 
peptides. We were able to observe only dimers being eluted in case of the S463D 
phosphomimetic peptides, instead of trimers with wild-type and S463A peptide.  
CK2 is an ubiquitously expressed serine/threonine protein kinase found in all mammalian 
tissues (Issinger, 1993). CK2 is reported to play a role in the regulation of cellular 
morphology which includes cell polarity and the cytoskeleton across a variety of biological 
systems that expands from unicellular organisms to higher eukaryotes (Canton and Litchfield, 
2006). From in silico analysis we predicted CK2 kinase phosphorylation at three residues, 
Ser463, Ser174, and Ser98 that are currently investigated. Here, we demonstrated a CK2α 
kinase interaction with CRN2. Further, in vitro phosphorylation studies confirmed a 
phosporlyation by CK2α kinase. Actually, we study the CK2α dependent phosphorylation of 
CRN2 and possible changes in its interaction with the Arp2/3 complex and with cofilin in 
vivo employing 2D gel electrophoresis and co-immunopreciptation studies with and without 
specific CK2 inhibitors (data not shown).  
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In this respect, at least three major functions are constituted by the coiled coil domains of 
short coronins. Apart from interaction with F-actin and homo-oligomerisation, they also 
interact with Arp2/3 complex (Gandhi and Goode, 2008a). CRN2 interaction with Arp2/3 
complex was already reported (see Fig.12). In CRN2, serine 463 at the coiled coil domain was 
predicted to be a conserved acidic motif which was similar to those found in Arp2/3-
activating proteins of the SCAR/WASP family (McArdle and Hofmann, 2008). CK2 kinases 
are shown to phosphorylate various proteins involved in actin polymerisation like WASP and 
MAPs (Canton and Litchfield, 2006). In specific CK2 kinase phosphorylation of VCA 
domain of WASP protein is reported to enhance activation of Arp2/3 complex resulting in 
increased actin polymerisation (Cory et al., 2003; Mullins et al., 1998). Similarly, the exact 
mechanism or significance of CK2 phosphorylation of CRN2 on Arp2/3 interaction currently 
is investigated and we may find a contribution to the regulation of CRN2 activity in actin 
dynamics. 
At the cellular level the activity of CRN2 wild-type as well as CRN2 S463D phosphomimetic 
and S463A non-phosphorylateable mutant were studied with respect to a couple of cell based 
assays, like wound healing and single cell protrusion, and in vitro Arp2/3 mediated actin 
polymerisation assay. Our first results show that phosphomutant CRN2 S463D suppressed 
cell migration and formation of cellular protrusions compared to wild-type and S463A, which 
were similar to CRN1 activity (Cai et al., 2005). Coronins are reported to be molecular 
inhibitors of Arp2/3 by stabilising an inactive and closed form of this complex (Rodal et al., 
2005), however at the cellular level this turns out be an activating process for Arp2/3-
depedent processes like cell migration (McArdle and Hofmann, 2008). Further, our in vitro 
Arp2/3 mediated actin polymerisation studies using CRN2 peptides showed an enhanced 
inhibitory effect of S463D mutant compared to CNR2 wild-type. Our further studies aim to 
reveal the exact effect of CRN2 phosphorylation on Arp2/3 mediated actin polymerisation. 
6.4 Structural and functional diversity of novel CRN2 isoforms  
We identified two novel isoforms of CRN2, named CRN2i2 and CRN2i3. They do not arise 
from post-translationally modified ‘conventional’ CRN2i1, but they are encoded by a 
common, alternatively spliced transcript. A novel alternative exon, exon 1b, which contains 
two more start codons, replaces an untranslated exon, now termed exon 1a, preceding the 
normal start codon present in exon 2 of the CRN2 gene. Accordingly, two transcripts differing 
at their 5’ end code form three protein isoforms of CRN2 that vary in their N-terminal length. 
Expression of the largest CRN2 protein, CRN2i3, can be specifically induced by MyoD, 
while the other two smaller isoforms are repressed. Thus, CRN2i3 is expressed as part of the 
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myogenic differentiation program and is the only CRN2 isoform present in mature skeletal 
muscle tissue. The possibility that MyoD homo-dimers could bind directly to guanine-rich 
core promoter elements in CRN2 (Yafe et al., 2008) might explain how it alters, directly or 
indirectly, the transcription start site specificity within the unique CRN2 promoter. The 
prospect that the novel protein isoforms 2 and 3 may originate from alternative processing of 
a single primary transcript requires validation by the eventual isolation of a composite, 
elongated transcript encoded by both exons 1a and 1b. 
The mechanism by which myogenic regulatory factors operate on a single promoter to 
enhance transcript diversity by alternative processing of the primary transcript is known to 
involve RNA binding proteins such as MBNL and CELF, which have been genetically linked 
to several neuromuscular disorders (Yuan et al., 2007). The possibility should therefore be 
considered that such alternative splicing regulators play an accessory role downstream of 
MyoD to (de)stabilize or reconfigure a primary transcript comprising exons 1a, 1b and 
flanking introns (i.e. containing splicing factor binding motifs) resulting in the excision of 
different segments and the formation of distinctly processed CRN2 transcripts during 
myogenic differentiation in primates. 
The elongated N-terminus in CRN2i3 changed the oligomerization state of the protein. While 
CRN2 derived from kidney tissue (isoforms 1 and 2) forms trimers, CRN2i3 from skeletal 
muscle tissue eluted as a monomer from gel filtration experiments. Within the three-
dimensional structure, the N- and C-terminal ends of the coronin β propeller are in spatial 
vicinity (Fig.26). From this, two scenarios for an interaction can be envisioned; (i) an 
interaction of the additional secondary structure elements in the elongated N-terminus of 
CRN2i3 with the β-strand formed by residues 438-442 in the C-terminal extension causes 
conformational changes and prevents the following helical domain from engaging in a coiled 
coil; (ii) amino acid residues 1-47 from the additional N-terminal peptide directly interact 
with residues 489-527 in the coiled coil domain and thus prevent formation of a coiled coil. It 
remains to be seen how an interaction suggested in (ii) may be structurally achieved.  
The current model depicting coronin function shows a dual regulation in the F-actin turnover 
(Gandhi and Goode, 2008a). ‘Coronin’ recruits the Arp2/3-complex to the barbed end and 
protects growing actin-filaments from depolymerisation, but promotes cofilin-dependent actin 
sequestration at the pointed end of actin filaments. Additionally, CRN2 (Hasse et al., 2005; 
Spoerl et al., 2002).CRN4 (Galkin et al., 2008) and further coronins (Xavier et al., 2008) have 
been shown to bundle and crosslink F-actin in vitro. It is tempting to speculate that the 
oligomerization state of coronin proteins turns out as a mechanism controlling actin-related 
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cellular functions (see above). Intriguingly, both hepta-peptide motifs in the N-terminal 
domain of CRN2i3 contain additional predicted phosphorylation sites, where posttranslational 
modifications might assist in regulation of the CRN2 activities. 
Confocal microscopy analysis of endogenous CRN2 and of GFP-fusion proteins in various 
cells as well as differential centrifugation assays indicated a similar subcellular localization of 
the CRN2 isoforms. The GFP-fusion proteins associated with F-actin structures at cellular 
extensions and cytosolic F-actin fibers. We further used substrate-attached human primary 
macrophages that constitutively form well-defined podosomes (Linder et al., 1999) and could 
demonstrate that at least two CRN2 isoforms are a novel components of the F-actin-rich core 
structure of podosomes. While CRN2 does not seem to be essential for the formation of 
podosomes, it may affect their lifetime, internal actin turnover or function such as in matrix 
degradation. The finding, that CRN2 is essential for formation and function of invadopodia 
(see below), but not for the formation of podosomes, points to a different regulation of these 
complex invasion-mediating structures. 
Analyses of normal human skeletal muscle tissue showed a localization of CRN2i3 within the 
thin filament region of the sarcomere. Identification of novel components of the sarcomere is 
not uncommon. For example, myomesin-3 (Schoenauer et al., 2008), CAP-2 (Peche et al., 
2007) and leiomodin (Chereau et al., 2008) have been described recently. The physiological 
role of CRN2 within the thin filament structure is currently unclear. CRN2i3 may play a role 
either structurally, in the organization of the sarcomere via stabilization of the sarcomeric F-
actin bundles, or functionally, e.g. in force development. CRN2i3 further co-localized with 
the postsynaptic area and the junctional sarcoplasm of motor end-plates. Actin is also a known 
component of this structure (Hall et al., 1981) which is characterized by folds of the 
sarcolemma and clustered ligand-gated Na+/K+-channels (Guth, 1983);(Ogata, 1988). The 
actin cytoskeleton directly or indirectly seems to be involved in the formation and 
stabilization of the motor endplate (Hall et al., 1981; (Berthier and Blaineau, 1997) and 
(Blaineau, 1997; (Dobbins et al., 2006) however, the details are unknown. CRN2i3 represents 
as a novel candidate possibly involved in the formation of this part of the neuromuscular 
junction. ADF/cofilin and related proteins have been identified as binding partners of coronin 
proteins (Rosentreter et al., 2007);(Gandhi and Goode, 2008b) together regulating the 
sequestration of actin monomers. In skeletal muscle cofilin-2 is thought to be involved in 
muscle function and regeneration (Thirion et al., 2001). Mutations of cofilin-2 lead to rare 
congenital nemaline myopathy (OMIM 601443) characterized by severe proximal muscle 
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weakness and the presence of nemaline rod bodies (Emery, 1999). The latter finding provides 
a possible pathophysiological link between cofilin-2 mutations and CRN2i3. 
7.0 Expression of CRN2 in diffuse gliomas is related to malignancy 
The relationship between CRN2 expression and malignancy was only seen in diffuse gliomas. 
Other tumours, including the pilocytic astrocytoma, either expressed or did not express 
CRN2, irrespective of their malignancy. However, in these particular tumour entities the 
presence or absence of CRN2 appears to be a characteristic feature. For example, all pilocytic 
astrocytomas analysed in this study expressed CRN2. On the other hand, medulloblastomas 
and neuroblastomas never showed CRN2 in immunoreactive cells.  
Interactions between CRN2 and F-actin described above further strengthen the vitality of the 
CRN2–F-actin system, together contributing to the malignancy of diffuse gliomas. Since the 
expression level of CRN2 in diffuse gliomas clearly correlated with the degree of malignancy, 
we focused on this specific group of tumours to further investigate, whether the function of 
CRN2 in glial cells is related to its effects in diffuse gliomas. The hypothesis that CRN2 
expression in glial cells is related to migration is supported by our observation, wherein 
CRN2 was found to be highly expressed in reactive astrocytes and microglial cells that had 
been triggered by circumscriptive tumour, infarct and traumatic lesions. Moreover, our 
previous studies of CRN2 expression in migratory progenitor cells in the developing mouse 
brain define a critical function of CRN2 in cell migration (Hasse et al., 2005).  
Further to envisage the role of CRN2 in glioma cells, we efficiently silenced CRN2 
expression through lentivirally delivered shRNA-cassette expression vectors in these cell lines 
and analysed various malignancy associated cellular activities. These experiments validated 
our immunohistochemistry results and strongly supported our hypothesis that CRN2 
expression in diffuse gliomas is responsible for cell migration and invasion of healthy tissue. 
Silencing CRN2 expression in glioblastoma cell lines significantly reduced cell proliferation 
rates; however, analysis of the number of cells in the G0/1, S or G2/M phases of the cell cycle 
showed no difference. This indicates that there is neither an inhibition of the cell cycle nor a 
difference in the tumour cell growth fraction, but a difference in the duplication time, possibly 
due to a role of CRN2 in the formation of the cytokinetic actin ring (Glotzer, 2005). This view 
is supported by the previously reported role of CRN2 in cytokinesis (Rosentreter et al., 2007).  
The knockdown of CRN2 expression also reduced cell migration, the formation of 
invadopodia and invasion into the extracellular matrix. The degree of migration and invasion 
into healthy tissue is a critical parameter which defines malignancy in diffuse gliomas and 
moreover, a critical factor that limits the success of surgery (Kleihues and Cavenee, 2000). 
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Invasion assays showed a prominent reduction in case of A172 glioblastoma CRN2 
knockdown cells. In addition these cells also showed a reduced secretion of matrix 
metalloproteinases (MMPs), while U373 CRN2 knockdown cells failed to invade a 3D-
gelatin matrix. In particular, secretion of MMP-2 (gelatinase A) has been shown to play a 
central role in glioma invasion (Binder and Berger, 2002; Lefranc et al., 2005; Rao, 2003). A 
role of CRN2 in secretion of epinephrine has been previously found in PC-12 cells 
(Rosentreter et al., 2007). 
CRN2 knockdown in the glioblastoma cell lines did not show identical patterns in the reduced 
capacity of matrix metalloproteinase activity and invadopodia formation. This strengthens the 
hypothesis that CRN2 has different effects in different tumours, including different 
glioblastomas. On the other hand, CRN2 is stably expressed in glioblastomas and in two types 
of glioblastoma cell lines studied, CRN2 knockdown led to an inhibition of cell proliferation, 
migration and invasion, suggesting a general role of CRN2 in the malignant phenotype of 
glioblastomas. We aim to conduct further studies using transgenic mouse models to explain 
the exact function CRN2 exerts towards local actin dynamics, which in turn will define the 
role of CRN2 in the development of gliomas. 
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IV. Materials and Methods 
 
1.0 Kits and Regeants  
NucleoSpin Extract 2 in 1      Macherey-Nagel 
Quick Change Site-Directed Mutagenesis kit  Stratagene 
pGEM-Teasy Vector kit      Promega 
Pure Yield Plasmid System     Promega 
Actin Polymerisation Biochem Kit    Cytoskeleton 
Nucleobond AX 100 and 500     Macherey & Nagel 
NucleoSpin Plus      Macherey & Nagel 
1 kb DNA-marker      Gibco-BRL 
High molecular weight protein marker   Amersham Biosciences 
Prestained protein marker     Bio-Rad 
Protein marker for gel filtration    Amersham Biosciences 
Drystrip gel pI 3-10, 7 cm     Amersham Biosciences 
IPG buffer       Amersham Biosciences 
IPGphor isoelectric focusing units    Amersham Biosciences 
Lipofectamine 2000      Sigma 
Cellfactine       Sigma 
CytoSelect 96-well Cell Invasion Assay kit   CELL BIOLABS 
QMTT Cell Viability Assay kit    BioCat 
SensoLyte 520 Generic MMP assay kit   Mobitec 
1.2 Enzymes, antibodies, radioactive probes, antibiotics, inhibitors 
1.2.1 Enzymes for molecular biology 
Calf Intestinal Alkaline Phosphatase (CIP)   Boehringer 
Klenow fragment       Boehringer 
Lysozyme       Sigma 
Proteinase K       Sigma 
T4 DNA ligase      Boehringer 
Taq-polymerase      Boehringer 
Pfu DNA Polymerase      Promega 
AcTEV Protease      Invitrogen 
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1.2.2 Inhibitors 
Complete mini protease inhibitor cocktail   Roche 
PMSF (phenylmethylsufonylfluoride)   Sigma-Aldrich 
Ellagic acid       Calbiochem 
DMAT        Calbiochem 
1.2.3 Antibodies 
1.2.3.1 Primary antibodies 
Mouse anti-GFP-antibody mAb K3-184-2   Noegel et al., 2004 
Mouse-anti-annexin 7-antibody mAB 203-217  Clemen et al., 2000 
Mouse-anti-β-actin-antibody     Sigma-Aldrich 
Goat-anti-GST-antibody     Amersham Biosciences 
Mouse-anti-CRN2 antibody K6-444-4   Spoerl et al. 2002 
Mouse monoclonal anti-GFP mAb K3-167-2  Noegel et al., 2004 
Rabbit anti-Phosphoserine     ZYMED laboratories 
Rabbit Anti-p34-Arc/ARPC2     upstate 
Rabbit Anti-Cofilin      Sigma 
1.2.3.2 Secondary antibodies 
Goat-anti-mouse-IgG, peroxidase-conjugated  Sigma-Aldrich 
Goat-anti-rabbit-IgG, peroxidase-conjugated   Sigma-Aldrich 
Goat-anti-mouse-IgG, Cy3-conjugated   Sigma-Aldrich 
Rabbit-anti-mouse-IgG, Alexa 488-conjugated  Sigma-Aldrich 
Rabbit-anti-mouse-IgG, Alexa 586-conjugated  Sigma-Aldrich 
Goat-anti-rabbit-IgG, FITC-conjugated   Sigma-Aldrich 
TRITC-labelled Phallodine     Sigma-Aldrich 
1.2.4 Antibiotics 
Ampicillin       Sigma 
Kanamycin       Sigma 
Tetracycline       Sigma 
Gentamicin       Sigma 
G418        Sigma 
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1.2.5 Radiolabelled nucleotide 
α-32P -deoxyadenosine triphosphate, (10 µCi/µl)  Amersham 
1.3 Reagents  
acrylamide (Protogel: 30: 0.8 AA/Bis-AA)   National Diagnostics 
agarose (electrophoresis grade)    Life Technologies 
acetone       Riedel-de-Haen 
APS (Ammoniumperoxodisulfate)    Fluka 
Bacto-Agar, Bacto-Tryptone     Difco 
Benzamidine       Sigma-Aldrich 
Bromophenol blue (Na-salt)     Serva 
BSA (bovine serum albumin)     Sigma-Aldrich 
Chloroform       Riedel-de-Haen 
Calcium chloride      Sigma-Aldrich 
Coomassie-brilliant-blue R250    Serva 
p-coumaric acid      Fluka 
DMSO (Dimethyl sulfoxide)     Merck 
DTT (1,4-dithiothreitol)     Gerbu 
EDTA (Ethylenediaminetetraacetic acid)   Merck 
EGTA [ethylene-glycol-bis(2-aminoethylether)- 
N,N,N´,N´-tetraacetic acid]     Sigma-Aldrich 
Acetic acid       Riedel-de-Haen 
Ethanol       Riedel-de-Haen 
Ethidium bromide      Sigma-Aldrich 
FCS (fetal calf serum)      Sigma-Aldrich 
Formamide       Merck 
Formaldehyde       Sigma-Aldrich 
Glucose       Sigma-Aldrich   
Glycine       Degussa 
Glycerol       Oxoid 
IPTG (isopropyl β-D-thiogalactopyranoside)   Sigma-Aldrich 
isopropanol        Merck 
HEPES [(N-2-hydroxyethyl)piperazine-N´- 
(2-ethansulfonic acid)]     Sigma-Aldrich 
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β-mercaptoethanol      Sigma-Aldrich 
Methanol       Riedel-de-Haen 
Mineral oil       Amersham Biosciences 
MOPS (g-[Morpholino] propanesulfonic acid  Gerbu 
Ni-NTA agarose      Qiagen 
Nucleosidtriphosphate     Roche 
Nonidet-P40 (Nonylphenyl-polyethylenglycerine)  Fluka 
Paraformaldehyde      Sigma-Aldrich 
PIPES (1,4-piperazindiethansulfonic acid)   Sigma-Aldrich 
Ponceau S-concentrate     Sigma-Aldrich 
Protein-A-sepharose      LifeTechnologies 
Phalloidin TRITC-conjugated    Sigma-Aldrich 
SDS (sodium dodecylsulfate)     Serva 
Sucrose       Fluka 
Sodium azide       Merck 
TEMED (tetramethylethylenediamine)   Merck 
Tris (hydroxymethyl) aminomethane    Sigma-Aldrich  
Triton-X-100 (t-ocytlphenoxypolyethoxyethanol)  Merck 
Tween 20 (Polyoxyethylensorbitanmonolaurate)  Sigma-Aldrich 
X-gal (5-bromo-4-chloro-3-indolyl- 
β-galactopyranoside)      Roth 
Yeast extract       Oxoid 
1.4 Plasmids 
pEGFP-C1       Clontech 
pcDNA3.1/myc-His      Invitrogen 
pQE-30       Qiagen 
pVSV-G       BioCat 
pPACKH1-GAG      BioCat 
pPACKH1-REV      BioCat 
pLKO.1 -puro empty vector only    Open Biosystems 
pLKO.1- puro non-target-shRNA    Sigma 
pLKO.1-puro-GFP      Sigma 
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1.4.1 Oligonucleotides 
Coro3mutS98DF 5’ GGTCATTGCCAGCGGTTCAGAGG 3’ 
Coro3mutS98DRev  5’ CCTCTGAACCGTCGGCAATGACC 3’  
Coro3mutS174DF 5’ GACGATATGCATGACGACATGATTTACAATGTGAGCTGG 3’ 
Coro3mutS174DRev  5’ CCAGCTCACATTGTAAATCATGTCGTCATGCATATCGTCC3’ 
Coro3mutS463DF 5’ GCAATCAAGATGAGCGTATTTCCAAGTTAGAACAGCAGATGGC3' 
Coro3mutS463DRev  5’ GCCATCTGCTGTTCTAACTTGTCAATACGCTCATCTTGATTGC 3’ 
Coro3mutS463AF 5’ CAATCAAGATGAGCGTATTGCCAAGTTAGAACAGCAGATGGC3’ 
Coro3mutS463ARev  5’ GCCATCTGCTGTTCTAACTTGGCAATACGCTCATCTTGATTGC 3’ 
Coro3 shRNA  5’CGTCCACTACCTCAACACATT 3’ (TRCNOOOOO62777) 
1.5 Bacterial host strains 
E. coli XL1 blue       Bullock et al., 1987 
E. coli JM 109       Yanisch-Perron et al., 1985 
E. coli DH5α       Hanahan, 1983 
E. coli M15       Qiagen 
E.coli BL21       Studier and Moffatt, 1986 
1.6 Insect cell lines 
Sf-9 cells       Invitrogen  
Sf-High five cells      Invitrogen  
1.7 Mammalian cell lines    
HEK293       Graham et al., 1977 
TN        BioCat 
Cos7        Gluzman, 1981 
U372        (Thal et al., 2008) 
A172        (Thal et al., 2008) 
1.8 Media and buffers 
All media and buffers were prepared with deionised water, filtered through an ion-exchange 
unit (Membra Pure). The media and buffers were sterilized by autoclaving at 120ºC and 
antibiotics were added to the media after cooling to approx. 50ºC. For making agar plates, a 
semi-automatic plate-pouring machine (Technomat) was used. 
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1.8.1 Media for E. coli culture 
LB medium, pH 7.4       (Sambrook, (1989)) 
SOC medium, pH 7.0      (Sambrook, (1989)) 
1.8.2 Media for Mammalian cell culture 
DMEM (4,500 mg/l glucose)     Sigma-Aldrich 
DMEM (1,000 mg/l glucose)     Sigma-Aldrich 
1.8.3 Media for Insect Cell Culture 
SF-900 III SFM      GIBCO 
Express FIVE SFM      GIBCO 
1.9 Instruments and Equipments 
All the instruments that were used in this thesis work were from Department Facilities. 
1.10 Immunoblotting and antibodies 
For Western blot analysis samples were prepared according to standard procedures (Laemmli, 
1970) (Towbin et al., 1979). Detection of CRN2 was done with mAb K6-444 (Smith et al., 
1999), β-actin was detected by mAb AC 40 (Sigma).  
1.11 Mammalian cell culture  
HEK293 human embryonic kidney cells (ATCC: CRL-1573) ,HaCaT human keratinocytes 
(Boukamp et al., 1988), U373, A172, Cos7 and C2F3 were grown in Dulbecco's modified 
Eagle's medium (DMEM, 4.5 g/l glucose, Sigma) supplemented with 10% fetal calf serum 
(Biochrom), 1 mM sodium pyruvate (Sigma), 2 mM L-glutamine (Sigma), 100 units/ml 
penicillin G, and 100 µg/ml streptomycin (Invitrogen). In case of NIH3T3 murine fibroblasts 
(ATCC: CRL-1658) DMEM with 1 g/l glucose was used. PC-12 cells (ATCC: CRL-1721) 
were cultured in suspension in RPMI 1640 medium with 25mM HEPES pH 7.4, 
supplemented with 10% horse serum, 5% FCS, 4 mM L-glutamine, 100 U/ml penicillin G and 
100 µg/ml streptomycin. All cells were grown at 37 °C with 5% CO2.  
Electroporation of HEK293 and PC-12 cells was done by electroporation ((Rosentreter et al., 
2007)stably transfected HEK293 cell clones were selected in culture medium containing 1200 
µg/ml geneticin (G418; Invitrogen). To stably express CRN2 in HaCaT cells they were 
retrovirally transduced according to (Clemen et al., 1999). 
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1.12 2D-gel electrophoresis  
Two-dimensional gel electrophoresis in conjunction with immunoblotting was performed 
according to (Clemen et al., 2005). Incubation with primary antibody was followed by 
incubation with goat anti-mouse IgG coupled to horseradish peroxidase (Sigma); visualisation 
was done by enhanced chemiluminescence and exposure to x-ray films (Kodak). 
CRN2 was detected with mAb K6-444 (Spoerl et al., 2002) mAb 203-217 specifically 
recognized annexin A7 (Selbert et al., 1995). ß-COP was detected using mAb maD 
((Pepperkok et al., 1993), sarcomeric actin was recognized by mAb 5C5 (Sigma), and anti-
BiP/GRP78 was from Transduction Laboratories. Furthermore a rabbit polyclonal antibody 
against myomesin (1:200; a gift from Peter van der Ven, Bonn), a rabbit polyconal antibody 
against desmin (1:200; 2203PDE; Euro-Diagnostica), a sheep polyclonal antibody against the 
skeletal muscle ryanodine receptor (RyR1; 1:100; 70372(27); Upstate Biotechnology; 
developed by Kevin P. Campbell), and a monoclonal antibody against actin (1:100; AC40; 
Sigma) were used. 
1.13 Statistical methods 
Statistical analysis was performed using ANOVA or Student's t-test, as appropriate. The exact 
probability values and the significance of an analysis as well as the number of independent 
experiments and repeated measurements are indicated. 
 
Most of the specific experimental procedures described in the following paragraphs have been 
included in preliminary publications prepared from this thesis work, as listed at the end of the 
Introduction section. Therefore, where possible, descriptions of the experimental procedures 
have been shortened. Moreover, the experimental procedures are categorized according to the 
separate parts presented within the Results section. 
2.0 Role of CRN2 in cellular processes      
2.1 Generation of EGFP–fusion constructs of CRN2 domains 
Plasmids EGFP–CRN2NWDC (human, full-length, aa 1–474; NM_014325), EGFP–
CRN2∆CC (aa 1–444), and EGFP–CRN2∆NC (aa 72–404) are described in Spoerl et al. 
(Spoerl et al., 2002). pEGFP–CRN2WD (aa 72–299), pEGFP–CRN2NC (aa 1–71 fused to aa 
300–474), and pEGFP–CRN2NGC (aa 1–71 fused to aa 300–474 via a 5-glycine loop), which 
code for truncated EGFP–CRN2 fusion proteins as well as the retroviral vector GFP–hCRN2–
BMN were generated according to (Rosentreter et al., 2007). 
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2.2 Subcellular fractionation  
Differential centrifugation was done according to (Fox, 1985; Lehtonen et al., 2002; Spoerl et 
al., 2002; Tohyama et al., 1994). For F-actin depolymerization, confluent HaCaT or HEK293 
cell monolayers were incubated in normal cell culture medium containing 5 µM latrunculin B 
(30 min; Sigma) Ref: Rosentreter. Sample volumes of the Triton X-100-soluble fraction, the 
10,000 g pellet (highly crosslinked actin filaments), the pellet of 100,000 g (free or loosely 
crosslinked actin filaments associated with membranes), and the supernatant of 100,000 g 
(cytosolic fraction) (Fox, 1985; Lehtonen et al., 2002; Spoerl et al., 2002; Tohyama et al., 
1994) were normalized to the original number of cells used. 
2.3 RNAi silencing 
To reduce the amount of CRN2 protein in murine NIH3T3 fibroblasts a siRNA SMARTpool 
directed against murine CRN2 was obtained from Dharmacon (CORO1C, Cat # M-007778-
00-50), which had been derived from the sequence NM_011779. The siRNA pool contains 
four different siRNA complexes. Transfection of the siRNA duplexes was done according to 
Rosentreter et al, 200x.  
2.4 Immunofluorescence, confocal microscopy, and life cell imaging 
To visualize endogenous CRN2 and F-actin, HaCaT cells were either first fixed in 4 °C cold 
4% paraformaldehyde for 20 min followed by permeabilization with 0.5% Triton X-100 in 
PBS or first permeabilized and then fixed. HEK293 cells were fixed and then permeabilized. 
Immunostaining was performed according to (Spoerl et al., 2002). Secondary IgG were goat 
anti-mouse coupled to Alexa 488 or Cy3 (Molecular Probes and Sigma). F-actin was labelled 
by incubation for 60 min with 200 ng/ml TRITC– or FITC–phalloidin (Sigma), nuclei were 
visualized by incubation for 60 min with 100 ng/ml DAPI (Sigma), both together with the 
secondary antibody. Appropriate control experiments were performed. Images were recorded 
with a Leica DM IRBE microscope and TCS SP confocal laser scanning technology with 
TCSNT software. Image processing was done with Adobe PhotoShop.For cell migration and 
cell activity assays live cell imaging was performed using the Leica DM IRE 2 microscope 
and Leica DFC 350 FX camera with Leica FW 4000 software. In all these experiments cells 
were grown at 37 °C with 5% CO2. 
2.5 In vitro wound healing, proliferation, cytokinesis, and cell activity assays 
For in vitro wound healing a confluent layer of stably transfected HEK293 cells or of siRNA-
treated NIH3T3 cells was scratched with a 27-gauge needle. The culture medium was 
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changed to remove detached cells or debris. Closure of the wound was followed by recording 
an image every 10 min with the equipment described above. For calculation of the velocity 
of the wound healing the distance of the wound borders at 1 h and 11 h after scratching were 
determined in at least three positions. Three (HEK293) or four (NIH3T3) independent 
experiments were performed. To measure the proliferation rate, stably transfected HEK293 
cells were seeded at 106 cells/10-cm culture dish. After 3 days the cells from three 
independent experiments were trypsinized and counted again. To reveal defects in the 
cytokinesis, stably transfected HEK293 cells were seeded at 105 cells/10-cm culture dish and 
the relative amounts of multinuclear cells were determined by fluorescent microscopy after 3 
days of cultivation from two independent experiments. To visualize the activity of stably 
transfected HEK293 cells, they were seeded at low concentrations. 12 h later the GFP 
fluorescence signal of single cells was recorded for 30 min with a Leica DM IRE 2 
microscope and a Leica DFC 350 FX camera with Leica FW 4000 software. For each 
population the number of forming and retracting protrusions of single cells were determined. 
Similarly, the dynamics of GFP–CRN2 and RFP–actin were recorded by confocal microscopy 
(Leica DM IRBE microscope and TCS SP confocal laser scanning technology) in double-
transfected HEK293 cells. Every 10 s a 3-fold averaged image of single-cellular protrusions 
was taken. 
2.6 Co-immunoprecipitation 
1.5×108 HEK293 cells stably transfected with EGFP–CRN2 were treated for 30 min with 5 
µM latrunculin B (Sigma) in order to prevent unspecific co-precipitation of proteins bound to 
F-actin, washed twice with PBS, resuspended in 6 ml immunoprecipitation (IP) buffer (0.33× 
PBS pH 7.4, 2 mM benzamidine, 4mM DTT, 2mM EDTA, 0.5 mM PMSF, 0.5% Triton X-
100 (added after sonication)), sonicated, and microscopically examined to confirm complete 
cell lysis. The resulting lysate was centrifuged at 2000×g for 3 min at 4 °C and precleared 
prior to immunoprecipitation with equilibrated Protein G sepharose beads for 30 min. 3ml of 
pre-cleared supernatant were incubated with 500 µl of anti- GFP mAb (K3-184 or K3-167; 
(NH4)2SO4-concentrated hybridoma supernatant; (Noegel et al., 2004)) 7 µl Triton X-100 
and 70 µl protein G sepharose beads at 4 °C for 1.5 h. The beads were washed four times with 
1 ml IP buffer, incubated with 2× SDS–sample buffer for 5 min at 95 °C, and analyzed by 
immunoblotting using antibodies specifically recognizing CRN2, p34-Arc (rabbit polyclonal 
Ab, Upstate), and cofilin (rabbit polyclonal Ab, Sigma). For control, the experiment was 
carried out with cell lysate or with anti-GFP-mAb only. Immunoblotting with anti-
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BiP/GRP78 (Transduction Laboratories) and anti-β-actin (Sigma) was used for control to test 
for the specificity of immunoprecipitation. The experiment was done several times. 
3.0. Expression of CRN2 in diffuse gliomas is related to malignancy 
3.1 Neuropathology 
We have studied 69 biopsy and five autopsy cases by means of immunohistochemistry, and 
24 additional cases by immunoblotting, for the expression of CRN2. For details refer to (Thal 
et al., 2008) 
3.2 Visualization of invadopodia 
Invadopodia of U373 and A172 glioblastoma cells were visualized according to (Chen W-T, 
1994; Osiak AE, 2005). U373 cells, which form wide-stretched cellular extensions, and A172 
cells were seeded at low density and grown for 24 h on cover slips that had a 3D coat of 
FITC-labelled fibronectin or FITC-labelled gelatin. Invadopodia are actin-rich finger-like 
protrusions under the ventral surface of a cell that localize matrix-degrading activity, extent 
into the extracellular matrix, and are recognizable by co-localization of invadopodia markers 
with the degradation of fluorescently labelled extracellular matrix (Weaver, 2006). 
3.3 Lentiviral transduction of shRNA vectors 
Small hairpin RNAs (shRNAs) were used to stably and specifically reduce the expression of 
CRN2 in human glioblastoma cells. shRNA-oligo cgtccactacctcaacacatt (TRCN0000062777) 
cloned into pLKO.1-puro (BioCat/SBI/Open Biosystems) led to a 95% reduction in the 
expression level of CRN2 (CRN2). Each shRNA plasmid was co-transfected into 293TN 
cells, together with the three lentiviral packaging plasmids, pVSV-G, pPACKH1-GAG and 
pPACKH1-REV (BioCat/SBI: LV500A-1). The resulting lentiviruses were used to infect the 
target glioblastoma cells (approximately 95% transduction efficiency), which were 
subsequently enriched/selected to 99.9% transduction efficiency within 7 days by addition of 
0.75 µg/ml puromycin to the growth medium. Control cells expressed pLKO.1-puro empty 
vector only (‘mock’; Open Biosystems, RHS4078), a pLKO.1-puro-non-target-shRNA 
construct (‘scrambled’; Sigma, SHC002), or positive control pLKO.1- puro-GFP (Sigma, 
SHC003). Transfections of 293TN (60 mm plates) and transductions of target cells (three 
infections of the same 60 mm target cell plate for each shRNA, with viral supernatant 
collected after 24, 48 and 72 h) were done according to the manufacturer’s protocol (SBI) and 
Ref: Thal et al., 2008. Transduction efficiency was determined from the fluorescent GFP-
positive control. 
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3.4 Determinations of Cell based assays. 
Here Cell based assays include cell proliferation rate, cell cycle state, cell motility, cell 
invasion, matrix metalloproteinase activity and cellular F-actin content.To measure cell 
proliferation rates, seeding/trypsination as well as colorimetric cell viability assays (QMTT 
Cell Viability Assay; BioCat Z5030007-BC; (T.Mosmann, 1983) were used. To determine the 
cell cycle distribution, standard propidium iodide fluorescence-activated cell sorting (PI-
FACS) analyses were performed. Cell motility was determined, employing live cell imaging. 
To determine cell invasion rates, CytoSelect 96-well Cell Invasion Assays (BioCat CBA-112-
CB), based on the principle of a Boyden Chamber with basement membrane-coated inserts, 
were employed. SensoLyte 520 Generic MMP assays (Mobitec: 71158AS) were used to 
determine the overall activity of matrix metalloproteinases. The F-actin content of 
glioblastoma cells was determined according to Cunningham (Cunningham, 1995). The 
knockdown of CRN2 was verified by immunoblotting of samples of cells from each 
experiment. 
4.0 Structural and functional diversity of novel CRN2 isoforms 
4.1 Immunofluorescence and immunohistochemistry 
Immunofluorescence imaging of cultured cell lines was performed according to (Thal et al., 
2008). Isolation of human myofibers was performed by manual separation of fresh muscle 
biopsies in “relaxation solution” (Vielhaber et al., 2000). Further details see (Xavier-C.P, 
2008) submitted for publication.  
4.2 Mammalian cell culture  
Human peripheral blood monocytes were isolated and differentiated into macrophages as 
described previously (Linder et al., 1999). For myogenic conversion of NIH3T3 fibroblasts a 
retrovirus derived from plasmid BMN-hMyoD-IRES-GFP (transfected into ΦNX-E cells) 
containing a cassette coding for human MyoD was used (Clemen et al., 1999). Highly 
efficient transfection of primary human macrophages with a CRN2 specific siRNA-pool 
(Dharmacon siGENOME siRNA # M-017331-00) was performed according to (Rosentreter et 
al., 2007) using a Microporator device (Peqlab). In vitro wound healing was performed as 
described earlier (Rosentreter et al., 2007). 
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4.3 RNA purification, northern blotting, 5’-RACE, 5’-RLM-RACE, and RT-PCR 
RNA-samples: Total RNA from cells was extracted using the RNeasy Mini kit (Qiagen); total 
RNA from murine tissues was prepared using a TRIzol (Invitrogen) protocol ((Chomczynski 
and Sacchi, 1987); total RNA from samples of human skeletal muscle biopsies was prepared 
with RNA-Magic (Bio-Budget) following the manufacturer’s protocol. In addition, a pool of 
RNA from adult human skeletal muscle was obtained from Clontech. 
Northern blotting: 30 µg of total RNA from murine ES-cells, undifferentiated C2F3 
myoblasts, differentiated C2F3 myotubes, and various murine organs were analyzed by 
northern blotting using full-length murine CRN2 (accession no. AF143957) and ß-actin 
cDNAs as probes. 5’-RACE: Standard 5’-RACE was performed on various samples of total 
RNA extracted from human skeletal muscle tissue. Reactions were carried out according to 
the manufacturer’s protocol (Roche, 5’/3’ RACE Kit 2nd Generation, #03353621001). The 
PCR products were cloned into pGEMTeasy vector (Promega) and sequenced. 
5’-RLM-RACE: RLM (RNA-Ligase Mediated)-RACE allows the amplification of cDNA 
only from full-length capped mRNA and determines the real 5-prime end of an mRNA. 5’-
RLM-RACE was performed on various samples of total RNA extracted from human skeletal 
muscle tissue and reactions were carried out according to the manufacturer’s protocol 
(Ambion, FirstChoice RLM-RACE Kit, #1700). Reverse transcription using random 
decamers was carried out at 49°C. PCR products from various primer pairs ((Xavier-C.P, 
2008) were cloned into pGEMTeasy or purified and sequenced directly. 
RT-PCRs: cDNA from human skeletal muscle total RNA was obtained using p(dN6)-
oligomers and M-MLV reverse transcriptase (Promega) at 37°C for 1 h. PCRs were 
performed according to Xavier et al. to confirm or expand the sequences of the different 
CRN2 clones identified by RACE. Fragments obtained were cloned into pGEMTeasy and 
sequenced or the PCR-products were purified and sequenced directly using a 377 ABI DNA-
sequencer (Applied Biosystems). 
4.4 Differential centrifugation, subcellular fractionation, and gel filtration 
Differential centrifugation was done according to (Spoerl et al., 2002), isopycnic separation 
on a discontinuous sucrose gradient according to (Clemen et al., 1999). For gel filtration 
analysis 100 mg of murine skeletal muscle or kidney tissue were lysed in 20 mM HEPES, 
pH 7.2, 1 mM EDTA, protease inhibitor cocktail, and sonicated. The lysate was centrifuged 
for 30 min at 10,000 g, followed by centrifugation of the supernatant at 100,000 g for 1 h. The 
latter supernatant was adjusted to 0.6 M KCl, incubated for 1 h at 4°C, and re-centrifuged at 
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100,000 g for 1 h. KCl minimizes interactions between CRN2 and other proteins as well as 
interactions between actin and myosin (Berryman et al., 1995). The supernatants were 
adjusted to 1 µg/µl protein, and 50 µl were separated on a Superdex G200 gel filtration 
column using the SMART system (Amersham Biosciences). 
4.5 Plasmids for expression of CRN2 isoforms 
To express human EGFP-CRN2i1 (‘conventional’ CRN2 isoform 1, accession no. 
NM_014325) in C2F3 myoblasts, an AgeI/BamHI EGFP-CRN2i1-837bp3’UTR cassette was 
retrieved from EGFP-CRN2i1 (Spoerl et al., 2002), blunt ended and cloned into the 
BamHI/NotI backbone of pBMN-Z (Nolan, Stanford University). Retroviruses derived from 
the resulting plasmid EGFP-CRN2i1-BMN transfected into ΦNX-E cells were used to infect 
C2F3 target cells according to (Clemen et al., 1999). For expression of EGFP-CRN2i1 in 
HEK293 cells construct EGFP-CRN2i1 (Spoerl et al., 2002), was used; stably expressing 
cells were obtained after neomycin selection. Primary human macrophages were transfected 
with EGFP-CRN2i1 using a microporator device (PeqLab; Erlangen, Germany) according to 
the manufacturer’s instructions. 
In vitro mutagenesis was employed to generate plasmids coding for the two additional 
isoforms. Plasmids EGFP-CRN2i1-BMN and EGFP-CRN2i1 were used as templates. See 
Ref. Xavier et al., submitted for publication for details. All CRN2 expression constructs were 
verified by restriction enzyme digest and sequencing.  
4.6 Bioinformatic analysis 
Genomic sequence data for CRN2 from 11 primates and 28 other mammals were retrieved 
from NCBI (http://www.ncbi.nlm.nih.gov) and Ensembl 
(http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000110880). Regions 
encompassing the 5' promoter up to exon 2 were assembled, aligned by CLUSTALW and 
scrutinized bioinformatically for promoter features, transcription start sites, coding regions, 
exon splice sites, regulatory elements, and further analyses as described in Xavier et al., 
submitted for publication.. 
5.0 Influence of Phosphorylation on Structure and function of CRN2 
5.1 Expression of wild-type and mutant CRN2 coiled coil peptides. 
Construct pQE30 harbouring CRN2 wild-type peptide (aa 300-474) was used as a template. 
Using primers CRN2mutS463DFor and Rev, CRN2mutS463AFor and Rev and the Quick 
Change Site-Directed Mutagenesis kit, CRN2 S463D (aspatate), S463A (alanin) were 
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obtained. Corresponding recombinant proteins were expressed and purified according to 
(Spoerl et al., 2002). 
5.2 In vitro wound healing and single protrusion assay 
Constructs pEGFP-CRN2 (Spoerl et al., 2002), and mutants pEGFP-CRN2-S463D and 
pEGFP-CRN2-S463A (obtained as described above) were transfected into HEK293 cells and 
used in wound healing and single cell protrusion assays according to (Rosentreter et al., 
2007). 
5.3 In vitro phosphorylation assay 
The assay was performed in a phosphorylation buffer that composed 10mM MgCl2, 50mM 
MOPS pH7.0, 150mM NaCL and α-32P-dATP, (10 µCi/µl, Amersham). CRN2 wild-type (aa 
300-474) (2.5µg), S463D (4.0µg), and S463A (4.0µg) peptides as well as CRN2 wild-type 
full-length (0.4 µg) and S463D (0.5 µg) proteins were added to the phophorylation buffer 
without α-32P-dATP. The reaction was initiated with CK2α (0.12µg) and CK2α dead (0.4µg) 
with final addition of radioactive dATP. Reaction volume was adjusted to a total of 100µl. 
The reaction mixtures were incubated for 1, 5, 10, 30, 60, and 90 mins at 300C. In order to 
terminate the reaction; each sample was placed on ice and 60mM EDTA and 1x SDS sample 
buffer were added to each. All the samples were analysed by SDS-PAGE followed by 
autoradiography.(Skjerpen et al., 2002) 
5.4 Actin polymerization assays  
Actin polymerization assays were performed using a pyrene actin assay kit (Cytoskeleton) in 
which the rate of pyrene-labelled G-actin conversion into F-actin is monitored. The pyrene 
conjugated G-actin stock was depolymerized (as per the manufacturer’s instruction) and spun 
at 100,000g for 1 h at 4 °C to minimize oligomers that may have formed during storage before 
use in the assay. The general actin buffer, Pyrene labelled G-actin and polymerisation buffer 
(Actin Polyermization Biochem Kit, Cytoskeleton) were incubated at RT for 15mins. GST–
VCA domain (final concentration of 18.9 nM) and Arp2/3 complex (final concentration of 37 
nM) were incubated either in the presence or absence of CRN2 wild-type peptide (aa 300-
474) or S463D mutant (final concentrations 1x, 0.8 µM, and 2x, 1.6 µM) with actin for 1min 
before the addition of polymerisation buffer. 
Fluorescence was read immediately after the addition of polymerisation buffer using a 
Fluorescence system (Photon technology international –PTI system) set on kinetic mode to 
read every 1 min for the duration of the assay. PTI system was adjusted to wavelengths as 
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follows: Excitation, 350 nM; emission, 407 nM; and sensitivity, maximum. The assay was 
conducted in black-walled clear-two side windows cuvettes. Mean value of the maximum 
slope of each polymerisation curve was measured  (Serrels et al., 2007) and used for statistical 
analyses. 
5.5 Co-immunoprecipitation 
HEK293 cells stably transfected with EGFP–CRN2 were treated for 24hrs min with CK2 
inhibitors DMAT (1.4 µM) and ellagic acid 0.4 µM (Calbiochem), and controls with 
equilvalent amounts of DMSO, washed twice with PBS, resuspended in 6 ml 
immunoprecipitation (IP) buffer (20mM HEPES pH 7.0, 100mM KCl, 0.5% NP-40, 1mM 
EDTA, ?mM PMSF, 10µg/ml 1,10-pheanthroline, 10µg/ml aprotinin, 10µg/ml leupeptin, 
10mM sodium fluoride and 2mM Sodium orthovanadate), sonicated, and the lysates were 
cleared at 13,000xg for 5mins and incubated for 1-2hrs with 500 µl of concentrated anti-GFP 
mAb K3-167 (Noegel et al., 2004). Beads were washed extensively with IP buffer before pre-
blocking with 5% BSA and further incubated overnight with GFP antibody. The immune 
complexes were collected and washed 5 times with IP buffer, separated by SDS PAGE and 
transferred to Nylon membrane, and further analyzed by immunoblotting using antibodies 
specifically recognizing CRN2, phosphorylated CRN2 (phosphoserine antibody, Zymed 
laboratories), p34-Arc (rabbit polyclonal Ab, Upstate), and cofilin (rabbit polyclonal Ab, 
Sigma).  
5.6 CRN2 pull down experiments 
For pulldown assays, GST-CK2 or CK2-dead fusion proteins were purified from bacteria. The 
GST fusion proteins were supplemented with 100µl of equilibrated glutathione beads and 
incubated under constant rotation for 2hrs at 40C. After washing 4-5 times with washing 
buffer (4.3mM NaH2PO4, 1.47mM KH2PO4, 1.37mM NaCl, 2.7mM KCl) aliquots of the 
beads, now carrying the GST-CK2 fusion proteins, were incubated together with extracts 
from equal numbers of HEK293 cells (1.5 x 108) either expressing GFP-CRN2 wild-type, 
GFP-CRN2-S463D, or only the endogenous CRN2 protein. Alternatively, the aliquots were 
incubated with lysates of bacterial cells expressing His-CRN2-wild-type or His-CRN2-S463D 
C-terminal peptides. Incubation was done for 2hrs at 40C to pull down respective proteins. 
Cell extracts were prepared by lysing HEK293 cells in lysis buffer A (10mM HEPES pH7.9, 
10mM KCl, 0.1mM EDTA, 1mM DTT, 0.5mM PMSF, 0.5% NP40) and M15 bacterial cells 
in lysis buffer B (10mM DTT, 0.5mM PMSF, 2mM Benzamidin, 10µg/ml Aprotinin and 
leupeptin, 200mM NaCl, 5% Glycerine, 100µ/ml lysozyme and 0.5% NP40), incubation for 
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30mins at 40C, sonication, and the supernatant was collected by centrifugation for 5mins at 
13,000rpm. Protein bound beads were washed 10 times with washing buffer (4.3mM 
NaH2PO4, 1.47mM KH2PO4, 1.37mM NaCl, 2.7mM KCl with 5% glycerine and 30mM 
NaCl) and analysed by SDS-PAGE and immunoblotting. Control experiments were 
performed with GST or GFP alone. 
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VI. Appendix 
 
1. Abbreviations 
 
APS  ammonium persulphate 
ATP    adenosintriphosphate 
Bp    base pair(s) 
BSA    bovine serum albumin 
cAM    cyclic adenosine monophosphate 
cDNA    complementary DNA 
C. elegans   Caenorhabditis elegans 
CIAP    calf intertinal alkaline phosphatase 
dNTP    deoxyribonucleotide triphosphate 
CRN2    Coronin 1C, Coronin 3 
DMSO    dimethylsulphoxide 
DNA    deoxyribonucleic acid 
DNase    deoxyribonuclease 
ds DNA   double strand DNA 
DTT    1,4- dithiothreitol 
ECL    enhanced chemiluminescence 
E. coli     Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
EGTA    ethyleneglycol-bis(2-amino-ethylene) N,N,N,N-tetraacetic acid 
FCS    fetal calf serum 
FL    Full length 
G418    geneticin 
EGFP    enhanced green fluorescent protein 
GST    glutathione S-transferase 
HEPES   N-(2-hydroxyethyl)piperazine-N´-2-ethanesulphonic acid 
HRP    horse radish peroxidase 
IgG    immunoglobulin G 
IPTG    iso-propylthio-galactopyranoside 
Kb    kilobase pairs 
kDa    kilodalton 
MES    morpholinoethansulphonic acid 
β-ME    beta-mercaptoethanol 
MOPS    Morpholinopropanesulphonic acid 
MW    molecular weight 
NP-40    nonylphenylpolyethyleneglycol 
OD    optical density 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffer solution 
PBG    phosphate buffer with fish gelatine 
PIPES    piperazine-N,N´-bis(2-ethanesulphonic acid) 
PMSF    phenylmethylsulphonylfluoride 
RNA    ribonucleic acid 
RNase    ribonuclease 
Rpm    rotations per minute 
SDS     sodium dodecyl sulphate 
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ss DNA   single strand DNA 
TE    Tris-EDTA 
TEMED   N,N,N´,N´-tetramethyl-ethylendiamine 
Tris    Tris-(hydroxymethyl)aminomethane 
TRITC    tetramethylrhodamine isothiocyanate 
Triton X-100   t-Octylphenoxypolyethoxyethanol 
Tween    20 polyoxyethylensorbitanmonolaurate 
UV    ultraviolet 
vol.    volume 
v/v    volume by volume 
w/v    weight by volume 
X-gal     5-bromo-4-chloro-3-indolyl-D-galactopyranoside 
 
 
   
 
Summary 
 
Coronins are in general versatile actin filament-crosslinking and bundling proteins. In human, 
seven subfamilies of coronins are identified. One of these proteins found ubiquitously 
expressed in human tissues is CRN2 (synonyms: coronin-1C, coronin-3). Here, we study in 
vivo and in vitro F-actin associated properties of CRN2. Using different GFP tagged 
structural domain proteins and RNAi mediated knock down of CRN2, we studied the role of 
these domains in various cellular activities like wound healing, formation of protrusions, 
proliferation, cytokinesis and endocytosis. We found an inhibitory effect of the WD repeat or 
coiled coil domain of CRN2 in specific to be profound on wound closure and formation of 
cellular protrusions. 
Screening of the CRN2 protein sequence for posttranslational modifications resulted in 
identification of Ser463 as a putative serine phosphorylation site located in the coiled coil 
domain. An important cytoskeleton regulator, CK2α kinase, was found to interact and 
phosphorylate this residue. The consequence of this phosphorylation is to regulate 
oligomerization of this domain as evident from gel filtration studies. Further, at the cellular 
level it induced a significant inhibitory effect on wound closure and cell protrusion as studied 
using a phosphomimetic S463D mutation. CRN2 like other coronins interacted with the 
Arp2/3-complex and cofilin. In addition, both wild type and phosphomutant CRN2 executed 
an inhibitory effect on Arp2/3-mediated actin polymerisation, however, this effect was more 
pronounced in the case of phosphomutant.  
Two novel CRN2 isoforms which differ in their N-terminal length were found to arise from 
an alternative exon, exon 1a, identified in intron 1. All three isoforms co-localize with and 
associate with F-actin. Biochemical evidence suggests that, in contrast to the conventional 
isoform 1 and the longer isoform 2, the largest isoform 3 exists as a monomer. Structural 
modelling reveals that this difference in the oligomerization state may result from an 
interaction of the elongated N-terminus of CRN2-isoform 3 with the C-terminal coiled coil. In 
addition, this isoform, which is expressed during the myogenic differentiation and in mature 
skeletal muscle tissue, was found as a novel component specifically localizing to sarcomeric 
F-actin as well as to the motor end plate.  
Further we performed a detailed study on the expression pattern of CRN2 in human brain 
tumours. We found a correlation between the number of CRN2 positive cells and the 
malignant phenotype in diffuse gliomas. In addition, CRN2 knockdown glioblastoma cells 
exhibited significantly reduced levels of cell proliferation, motility and invasion into the 
extracellular matrix. Our findings provide evidence for a contribution of CRN2 in the 
malignant progression of diffuse gliomas. 
   
 
Zusammenfassung 
 
Coronine gelten als vielseitige Aktinfilament-vernetzende und -bündelnde Proteine. In 
menschlichen Zellen wurden sieben Mitglieder der Coronin-Familie identifiziert. Eines dieser 
Coronine, das ubiquitär exprimiert wird, ist CRN2 (Synonmye: Coronin-1C, Coronin-3). In 
dieser Arbeit untersuchten wir die mit Aktinfilamenten assoziierten Funtionen von CRN2. Mit 
verschiedenen GFP-Fusionsproteinen von CRN2-Domänen und einer RNAi-vermittelten 
Herunterregulation von CRN2 haben wir als Funktionen von CRN2 z.B. die in vitro 
Wundheilung, Ausbildung von Zellfortsätzen, Proliferation, Zellteilung und Endozytose 
ermittelt. Dabei fanden wir hemmende Effekte verschiedener CRN2-Domänen, insbesondere 
in der Wundheilung und Ausbildung von Zellfortsätzen. 
Eine Analyse der CRN2 Aminosäuresequenz hinsichtlich posttranslationaler Modifikationen 
zeigte Ser463 in der Coiled coil-Domäne als eine mögliche Phosphorylierungsstelle. Wir 
konnten hier zeigen, dass die Kinase CK2, ein wesentlicher Regulator des Zyoskeletts, mit 
Ser463 interagiert und diesen Rest phosphoryliert. Als eine Konsequenz ändert sich der 
Oligomerisierungsstatus von CRN2, wie mit Gelfiltrationsexperimenten belegt werden 
konnte. Weiterhin zeigten Experimente mit der phosphomimetischen S463D CRN2-Variante 
signifikant hemmende Effekte auf die Wundheilung und Ausbildung von Zellfortsätzen. 
CRN2 interagiert wie andere Coronine mit dem Arp2/3-Komplex und mit Cofilin. 
Diesbezüglich zeigten Aktinpolymerisations-Versuche einen ausgeprägten hemmenden Effekt 
von normalem wie auch S463D CRN2, wobei die Mutante eine deutlichere Hemmung 
aufwies. 
Wir haben zwei neue Isoformen des CRN2 beschrieben, die sich in der Länge des N-
Terminus unterscheiden und durch Spleißen eines alternativen Exons entstehen. Alle drei 
Isoformen kolokalisieren und assozieren mit F-Aktin. Biochemische Untersuchungen zeigten, 
dass die längste Isoform 3 nicht wie die anderen beiden als Trimer, sondern als Monomer 
vorliegt. Strukturmodelle ließen hier vermuten, dass der Unterschied im 
Oligomerisierungsstatus von einer Interaktion des verlängerten N-Terminus mit dem C-
Terminus herrührt. Die Isoform 3 wurde während der myogenen Differenzierung exprimiert 
und ist die alleinige Isoform in reifem Skelettmuskel. Hier haben wir CRN2 als eine neue 
Komponente des Sarkomers und der motorischen Endplatte beschrieben. 
Darüberhinaus haben wir eine detaillierte Studie zur Expression von CRN2 in humanen 
Hirntumoren durchgeführt. Es zeigte sich eine Korrelation zwischen der Anzahl CRN2-
positiver Tumorzellen mit dem malignen Phänotyp Diffuser Gliome. Die Herunter-regulation 
von CRN2 in humanen Glioblastomzellen ergab signifikant verminderte Raten von 
Proliferation, Motiliät und Invasion in die Extrazellularmatrix. CRN2 könnte ein Faktor für 
die Ausbreitung oder die schlechte Prognse von Diffusen Gliomen sein. 
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